CA2055500A1 - Expression of polypeptides - Google Patents
Expression of polypeptidesInfo
- Publication number
- CA2055500A1 CA2055500A1 CA002055500A CA2055500A CA2055500A1 CA 2055500 A1 CA2055500 A1 CA 2055500A1 CA 002055500 A CA002055500 A CA 002055500A CA 2055500 A CA2055500 A CA 2055500A CA 2055500 A1 CA2055500 A1 CA 2055500A1
- Authority
- CA
- Canada
- Prior art keywords
- expression
- island
- heterologous polypeptide
- host
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 117
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 116
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 32
- 108020005065 3' Flanking Region Proteins 0.000 claims abstract description 30
- 108020005029 5' Flanking Region Proteins 0.000 claims abstract description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 24
- 230000001419 dependent effect Effects 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 230000008569 process Effects 0.000 claims abstract description 15
- 230000010354 integration Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 30
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 22
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 22
- 229960005356 urokinase Drugs 0.000 claims description 22
- 239000005018 casein Substances 0.000 claims description 21
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 21
- 235000021240 caseins Nutrition 0.000 claims description 20
- 108091026890 Coding region Proteins 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 235000013336 milk Nutrition 0.000 claims description 15
- 239000008267 milk Substances 0.000 claims description 15
- 210000004080 milk Anatomy 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 8
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 5
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 239000000868 anti-mullerian hormone Substances 0.000 claims description 4
- 102000000412 Annexin Human genes 0.000 claims description 3
- 108050008874 Annexin Proteins 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 50
- 108020004414 DNA Proteins 0.000 description 46
- 108010076119 Caseins Proteins 0.000 description 36
- 102000011632 Caseins Human genes 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 22
- 230000009261 transgenic effect Effects 0.000 description 19
- 239000012634 fragment Substances 0.000 description 17
- 235000021249 α-casein Nutrition 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000004520 electroporation Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000010367 cloning Methods 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 108020001096 dihydrofolate reductase Proteins 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- 101000910039 Bos taurus Alpha-S1-casein Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 239000013601 cosmid vector Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000021246 κ-casein Nutrition 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000009366 Alpha-s1 casein Human genes 0.000 description 1
- 108050000244 Alpha-s1 casein Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010054964 H-hexahydrotyrosyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000594820 Homo sapiens Purine nucleoside phosphorylase Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 101100005297 Mus musculus Cat gene Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 101000947125 Rattus norvegicus Beta-casein Proteins 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LTKCXZGFJFAPLY-OERIEOFYSA-N [1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]azanium;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LTKCXZGFJFAPLY-OERIEOFYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012256 transgenic experiment Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
This invention relates to processes and intermediates for improving the level of production of a desired polypeptide in a recombinant host whose genome has integrated into it an island of expression comprising in the 5' to 3' direction, a 5' flanking region, the heterologous polypeptide encoding sequence and a 3' flanking region. The island of expression of this invention permits the expression of the integrated heterologous DNA sequence to be substantially dependent on its copy number and to be substantially independent of its position of integration in the host genome.
Description
2~55500 PCT/US91/01222 Y,, L~
IMPROVED EXPRESSION OF POLYPEPTIDES
TECHNICAL FIELD OF INVENTION
This invention relates to processes and intermediates for improving the level of production of a desired polypeptide in a recombinant host. More particularly, this invention relates to an "island of expression" -- a segment of DNA which contains a 3NA
sequence encoding a heterologous polypeptide -- and the use of the island of expression to transfect a host.
Hosts harboring this island of expression produce a surprisingly high level of the desired heterologous polypeptide. Incorporation of the island of expression - `
into a host permits the-desired heterologous polypeptide to be expressed substantially independent of its position of integration in the host genome and substantially dependent on the number of copies of the island of expression which integrate into the host genome.
BACKGROUND ART
It is well known that polypeptides can be expressed and secreted by hosts transformed or transfected with a DNA sequence coding for that polypeptide. For example, Gllbert et al., United States Patent 4,565,785 (1986) and L. Villa-Komaroff et al., "A Bacterial Clone Synthesizing Proinsulin", :'-- ., - . . .
~ . '" ' ' ' , . ~ . ', '. ' .
, ' ', .' ' ' . , ' WO 91/131~ i i PCT/US91/01~22 `I
2~5S500 Proc. Natl. Acad. Sci. USA, 75, pp. 3727-31 (1978) have shown that a selected polypeptide can be synthesized within a bacterial host and excreted through the host membrane. A similar process can be carried out in animal cells. J. Doehmer et al., "Introduction Of Rat Growth Hormone Gene Into Mouse Fibroblasts Via A
Retroviral DNA Vector: Expression And Regulation", Proc. Natl. Acad. Sci. USA, 79, pp. 2268-72 (1982).
Recombinant proteins have even been expressed in mammals through transgenic incorporation of an expression system into the pronucleus of a fertilized embryo. D. Bucchini et al., "Pancreatic Expression Of Human Insulin Gene In Transgenic Mice", Proc. Natl.
Acad. Sci. USA, 83, pp. 2511-15 (19863; K. Gordon et al., "Production Of Human Tissue Plasminogen Activator In Transgenic Mouse Milk", Bio/Technoloay, 5(11), pp. 1183-87 (1987).
However, to date, none of these techniques has been consistently successful in permitting large amounts of a desired heterologous polypeptide to be expressed by a host which has integrated into its genome a heterologous polypeptide encoding sequence.
This is particularly surprising in view of the high level of native protein production occasioned from the very same expression control sequences in their native environments. For example, milk specific expression control sequences permit large amounts of native proteins, e.g., casein, to be produced in and secreted from mammary glands. The very same milk specific expression control sequences, however, have not been demonstrated to induce large amounts of heterologous polypeptides when operatively linked to heterologous polypeptide encoding sequences. See, for example, C.W.
Pittius et al., "A Milk Protein Gene Promoter Directs The Expression Of Human Tissue Plasminogen Activator ., , .
WO9l/13151 2~55500 PCT/US91/01222 cDNA To T~e Mammary Gland In Transgenic Mice", Proc.
Natl. Acad. Sci. USA, 85, pp. 5874-78 (1988). The level of expression in these latter constructions is also independent of the number of copies of the heterologous polypeptide encoding sequence integrated into the host genome. Furthermore, the level of expression is subject to positional effects, i.e., it is dependent on where the heterologous polypeptide encoding sequence is integrated into the genome. K.F.
Lee et al., "Tissue-Specific Expression Of The Rat Beta-Casein Gene In Transgenic Mice", Nucleic Acids Res., 16(3), pp. 1027-41 (19 8).
Accordingly, the need exists for a method of increasing the expression of DNA sequence encoding a heterologous protein or polypeptide independent of its site of integration in the host genome. Moreover, such methods should provide expression that is dependent upon the number of copies integrated into the host genome so that expression levels may be controiled.
DISCLOSURE OF THE INVENTION
The present invention solves these problems by providing an "island of expression" containing a DNA
sequence which codes for a desired heterologous polypeptide. The island of expression of this invention provides for the first time, high level, position-independent and copy number-dependent expression of a DNA sequence coding for a heterologous polypeptide.
As is depicted in Figure 1, the island of expression of this invention comprises, in the 5' to 3' direction, a 5' flanking region, a heterologous -polypeptide encoding sequence ~coding for the desired heterologous protein or polypeptide) and a 3' flanking region. The 5' flanking region comprises,-in the 5' . . . ., . , : ............ . , :, .. , ., .. ., . :
. - : . . , : .: : . , ~ , -WO 91/t31~ 5 ~ ' ~ `? ~ PCT/US91/01222 and 3' direction, 5' expression control sequences and a 5' untranslated region. The expression control sequences are operatively linked to the heterologous polypeptide encoding sequence. The 5' untranslated region begins at a transcription initiation site and ends at the translational start site of the heterologous polypeptide encoding sequence. The 3' flanking region comprises in the 5' to 3' direction, a 3' untranslated region, and 3' expression control sequences, those control sequences being operatively linked to the heterologous polypeptide encoding sequence. Finally, the 5' and 3' flanking regions of the island of expression invention are characterized by a sufficient size and structure effective to render the level of production of the desired protein or polypeptide substantially dependent on the copy number of the island of expression integrated into the host genome and substantially independent of its integration site.
This invention also relates to the use of the island of expression to transfect a host and to those transfected hosts. Hosts which have integrated the island of expression into their genome produce high levels of the heterologous polypeptide encoded by a DNA
sequence within that island of expression.
Furthermore, the expression processes of this invention are substantially dependent on the copy number of the island of expression integrated into the host genome and independent of the site of integration, which advantageously allows expression levels to be manipulated.
In a preferred e~bodiment of this invention, the island of expression also includes a DNA sequence coding for a signal peptide. This signal sequence coding region is fused to, and in reading frame with, - , , ,:
. .
, . ,,, . . ., .- . .. . .
WO 91/131~t z~55500 PCI/VS91/01222 ~ .
~ I.t,~ !
the 5' end of the heterologous polypeptide coding sequence. The signal sequence coding region is also operatively linked to the expression control sequences so as to permit a host whose genome carries this preferred island of expression to produce, secrete, and preferably process, the desired protein or polypeptide from the pre-protein or pre-polypeptide coded for by the combined signal-heterologous polypeptide coding sequence.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts a schematic representation of a typical "island of expression" (A) and a preferred "island of expression" (B) in accordance with this invention.
Figure 2 depicts the construction of a plasmid (CAS1288) containing the 5' and 3' flanking regions of bovine alpha S-1 casein.
Figure 3 depic~s the introduction of the urokinase structural gene into CAS1288 to yield CAS1295, the island of expression.
DETAILED_DESCRIPTION OF THE INVENTION
In order that the invention herein described may be more fully understood, the following detailed description is set forth.
In this description the following terms are employed:
Expression controi sequences -- DNA sequences that control and r~gulate expression of gene products at both the transcriptional and translational level when operatively linked to a structural gene (DNA
coding for a polypeptide). They include the promoter and enhancer regions, ribosome binding sites, : . , . . . :, . . . . . . ............ . ........... :
: . . . . . . . . ... . . : , : . .
WO91/13151 ~ ! ' PCT/US91/01222 .~".
2~55500 ''`"
polyadenylation signals and other sequences useful in the expression of genes.
Operatively linked -- the linking of 5' and 3' expression control sequences to a heterologous polypeptide encoding sequence so as to permit the expression control sequences to control and regulate the expression and production of the heterologous polypeptide.
Heterologous polypeptide encoding sequence --a DNA sequence coding for a desired polypeptide orprotein that is inserted into the genome of a host.
This DNA sequence codes for a polypeptide which is heterologous to either the host, the flanking sequences or both. The heterologous polypeptide encoding sequence optionally contains its own translational start signal at its 5' end and its own translational stop codon at its 3' end. The heterologous polypeptide encoding sequence may also contain its own signal sequence coding region.
Signal sequence coding region -- a DNA
sequence which encodes a sequence of typically hydrophobic amino acids called a signal peptide. The signal peptide allows a polypeptide to which it is attached to cross a biological membrane.
Isiand of expression -- a DNA construct comprising in the 5' to 3' direction, a 5' flanking region, a heterologous polypeptide encoding sequence and a 3' flanking region. The S' and 3' flanking regions are of sufficient size and structure to render the level of production of the desired protein or polypeptide substantially dependent on the copy number of the island of expression construct incorporated into the host genome and substantially independent of the position of integration of the island of expression in the host genome.
.: . .. -- - . ~. - .. . , .. ., :
s .~ . . . . . . : . : - .
. :' . ~ ' '. : ,~ ' ; ' ' . ' : . . ; ' , ~ ' : .:, .: ' ., - ,, , : :
, ~ ~, ., -. ~ . : ' . :
~ ........................... 2(~SSSOO . .
~ i I J~
5' flanking region -- is that part of the island of expression which is 5' to the heterologous polypeptide encoding sequence. It includes, in the 5' to 3' direction, 5' expression control sequences and a 5' untranslated region, the expression control sequences being operatively linXed to the heterologous polypeptide encoding sequence. The 5' untranslated region typically extends from a transcription initiation site to the translational start site of the heterologous polypeptide encoding sequence.
3' flanking region -- is that part of the island of expression which is 3' to the heterologous polypeptide encoding sequence. It includes, in the 5' to 3' direction, a 3' untranslated region, and 3' expression control sequences. The 3' flanking region may also include all or a portion of the coding sequence from the structural gene originally associated with the 3' flanking region.
DETAILED DESCRIPTION OF THE INVENTION
Although not wishing to be bound by theory, we believe that the island of expression allows as yet undefined factors within the 5' and 3' flanking regions to operate on the expression control sequences and to permit the heterologous polypeptide encoding sequence to be expressed at higher yields. Expression is also dependent on the number of copies of the island of expression construct incorporated into the host genome, thus allowing the level of polypeptide production to be modulated.
The large 5' and 3' flanking regions of the islands of expression of this invention may also provide a buffer zone so that the expression control sequences are isolated from host expression controls which may be exerted by the surrounding DNA into which ' WO91/131~1 PCTtUS91/0~222 ,~ S ~! ~ t ~ t; ~
., ,~ ~' ', 2~5sSOO
the island of expression has integrated. Therefore, no matter where in the host genome the island of expression integrates, the heterolo~ous polypeptide encoding sequence will be expressed at a high level.
It carries its own genomic environment along with it, as an "island of expression".
Although not wishing to be bound by theory, we believe that the majority of regions of DNA which may enhance expression from expression control sequences are found in the 5' and 3' flanking sequences of a given structural gene. Therefore, after isolation of a structural gene with its 5' and 3' flanking regions, the structural gene, in accordance with one embodiment of this invention, may be excised in whole or in part and replaced with any heterologous polypeptide encoding ~e~uence so as to permit expression at a level consistent with that of the original structural gene. Alternatively, the heterologous polypeptide encoding sequence may be inserted at the 5' end of the structural gene without concomitant removal of that gene. In that embodiment, the heterologous polypeptide encoding sequence will also be expressed at a level that is comparable to the expression level of the original structural gene.
Among the expression control sequences useful in the various embodiments of this invention are those which direct expression at hi~h levels in particular types of cells or at particular stages of cell growth or differentiation, or under specific culture conditions. Tissue-specific expression control sequences are preferred in the transgenic hosts of this invention.
If mammalian host cells are utilized, useful expression control sequences may be derived from native sequences encoding a highly expressed product from the .. : , WO91/~31~1 PCT/US91/01222 ~` ` 2~SS~;~)O
g host cell itself, or they may be derived from other eukaryotic genes with high levels of expression, such as ~-actin, collagen, myosin, albumin, metallothionein and human growth hormone.
A preferred embodiment of this invention provides for the production of proteins in transgenic mammals. This embodiment preferably uses expression control sequences which control and direct expression of gene products in mammary tissue, such as expression control sequences corresponding to casein promoters and the beta lactoglobulin promoter. The casein promoters may, for example, be selected from an alpha casein promoter, a beta casein promoter or a kappa casein promoter. More preferably, the casein promoter and associated expression control sequences are of bovine oriqin and most preferably are an alpha S-l casein promoter and associated expression control sequences.
Expression control sequences may even be derived directly from the cells which are to be used as the host for the island of expression construct. A
promoter and associated expression control sequences having the desired level of activity in the host must first be identified. The island of expression must be designed so that each island of expression construct which integrates into the host genome is expressed in a copy number-dependent, position-independent manner.
We describe here a means of identifying expression control sequences, cloning the required flanking regions containing these sequences, adding the heterologous polypeptide encoding sequence, and testing whether the resultant construct is an "island of expression" in accordance with this invention.
The first step is to determine a host and conditions which allow a gene homologous to that host to be expressed at a desired level or at specific 21!55500 - lo -times. In the case of tissue culture, CH0 cells growing on the collagen beads found in the VERAX~
system are preferably used.
To isolate the expression control sequences for a homologous gene that is expressed at high levels in host cells under selected conditions, an abundantly expressed RNA species must be identified. This may be achieved by preparing a cDNA library from polyA RNA
isolated from a selected host cell under selected conditions of induction and growth. The cDNA library is then screened using ~ labelled aliquot of the same RNA from which the cDNA library was produced. The most positive signals are indicative of those cDNAs whose RNAs are most abundant in the host cell under the selected conditions of induction and growth. The selected cDNAs may then be used to screen genomic DNA
libraries prepared from the selected host cells in order to select genomic DNA sequences that correspond to most abundant RNAs. These genomic sequences, typically in cosmids [T. Mani~tis et al., Molecular Cloninq: A Laboratory Manual, Cold Spring Harbor Laboratory (1982)], may then be analyzed to determine restriction sites, the amount of flanking sequences in the cosmid and the polypeptide coding regions contained therein.
Alternatively, but less preferably, the expression control sequence may be isolated by screening a host cell grown under selected conditions and induction for an abundantly produced protein or polypeptide. This is achieved by analyzing the total polypeptides produced from the host using either SDS
polyacrylamide gel electrophoresis (SDS PAGE) or two-dimensional gel electrophoresis. The most abundant polypeptides are identified by the strongest band in an SDS-PAGE g~l or the largest spot in a two-dimensional .- ~' " ' . ; : , ~
WO91/131~1 PCT/US91/01222 `~``` 2(~55500 gel. Once identified, the band or spot is excised from the gel, eluted, and subjected to automated protein sequencing. Oligonucleotides based upon the amino acid sequence obtained from the protein sequencing are then synthesized. ~hese oligonucleotides can then be labeled and used as probes to identify their corresponding genomic sequences from a cosmid library constructed from host cell DNA.
Once a sufficiently detailed restriction map of this abundantly expressed gene has been determined, the coding sequences and intervening sequences of the structural gene may be removed from the cosmids, for example, with appropriate restriction enzymes and replaced with the heterologous polypeptide encoding sequence. Alternatively, the heterologous polypeptide encoding sequence may be inserted 5' to the structural gene. In this embodiment, the structural gene need not be excised. According to a preferred embodiment, the heterologous polypeptide is urokinase, the DNA sequence of which has been isolated and cloned from a genomic library using published sequences as probes. A. Riccio et al., "The Human Urokinase-Plasminogen Activator Gene And Its Promoter", Nucleic Acid Res., 13(8), pp. 2759-71 (1985).
The resulting construct has the DNA sequence coding for the heterologous polypeptide flanked on both sides by the genomic sequences of the abundantly expressed gene which was originally isolated from the host cells. Constructs containing the ~arious lengths of 5' and 3' flanking sequences must be tested to determine what size flanking regions are necessary to direct expression of the heterologous polypeptide encoding seguence in a copy number-dependent, position-independent manner.
.,--.. . . . . . ....................................... .
.. ; ... . .. . . . ..... . . . .
- : .: , . : . ,.
WO91/131~1 PCTIUS91/01222 I ~
2~S i~ 12 -To determine that the isolated cosmid contains sufficient 5' and 3' flanking regions to permit an inserted heterologous polypeptide encoding sequence to be expressed at substantially the same level as that of the highly expressed homologous DNA
sequence, the selected DNA sequence is transfected into cells in tissue culture or introduced into the genome of an embryos to produce transgenic animals.
Preferably, the cells or embryo that will be used for ultimate production are employed in this step. The transformed hosts are then tested for the expression of the heterologous protein by any of a number of well-known assays. These include, but are not limited to, radioimmunoassay, ELISA, immunoblotting and assays which measure the activity of the desired polypeptide.
Alternatively and preferably, mRNA levels under a variety of growth conditions are used. This may be achieved by the Northern blot technique using the previously described oligonucleotides (corresponding to the polypeptide sequences) or the cDNAs identified previously as probes.
Because the expression control sequences selected from the host cells demonstrate the ability to direct expression of the homologous gene at a high level under known conditions (e.g., CHO cells growing on collagen beads in the VERAX~ system), it is expected that substantially the same level of expression of the heterologous polypeptide would be seen under those same conditions. Should the cosmid derived DNA sequence not provide such level of expression, then other cosmids containing different lengths of 5' and 3' flanking regions should be analyzed in substantially the same way until an appropriate DNA sequence is located.
The levels of production of the heterologous protein adduced by this sequence are then compared to ,. . , . ~ . ., , ,; ~ , ; ~
WO9ltl3151 2~55500 PcT/US9l/01222 the copy numbers of the integrated island of expression. copy number is determined by appropriate restriction enzyme analysis. The expression constructs which show position-independent, copy number-dependent expression are the optimal "islands of expression" in accordance with this invention.
According to a preferred embodiment the desired polypeptide is secreted by a host harboring an island of expression of this invention. Secretion of polypeptides is accomplished by fusing a DNA sequence coding for a signal peptide to, and in reading frame with, the DNA encoding the heterologous polypeptide.
The size of the signal peptide is not critical for this invention. All that is required is that the signal peptide be of a sufficient size and sequence to effect secretion of the heterologous polypeptide. The signal sequence encoding the signal peptide may be exemplified by signal sequences associated in nature with the expression control sequences, signal sequences associated in nature with the desired heterologous protein or polypeptide, signal sequences which are native to the host, signal sequences which are native to the source of the heterologous polypeptide, signal sequences which are native to the source of the expression control sequences and any other sequences encoding functional signal peptides.
Many of the proteins to be expressed are normally secreted and will have their own signal peptide which should be adequate to direct secretionO
In this case, the DNA encoding that signal may be included in the heterologous polypeptide encoding sequence that is inserted into the island of expre~sion. To produce a polypeptide that is not normally secreted, it is possible to use a signal sequence from polypeptides which are normally secreted - . . ..
,.
W09l~l315l l ~ PCT/US91/01222 ~, ? ~ 't ~ 4 from the host cells or from other secreted polypeptides. A preferred embodiment of this invention uses sequences encoding milk-specific signal peptides or other signal peptides useful in the maturation and S secretion of protein in mammary tissue. These include the signal sequence from alpha S-1 casein. If the heterologous polypeptide to be expressed is associated in nature with its own signal sequence, the signal sequence associated in nature with the heterologous polypeptide coding sequence is the more preferred signal sequence.
The necessary 5' and 3' flanXing regions are characterized by the ability to cause expression from the island of expression construct to be position-independent and copy number-dependent. The length of the flanking sequences is not critical as long as these properties are conferred to the expression construct.
The upper size limit is defined by the ease of manipulating the DNA. In the original source of the expression control sequences (in the animal or in the cell line), the expression control sequences are flanked, in theory, by the whole chromosome. Present techniques allow the ready manipulation of 40-50 kb segments of DNA. This requires the use of well-known cosmid technology. There may also be a limit on the size of DNA that can be injected through the needles used in embryo manipulations. The preferred technique is to use as large 5' and 3' flanking regions as possible to insure enough insulating region to confer copy number dependence and position independence.
The coding sequence of the desired heterologous polypeptide can be derived from either cDNA, genomic sequences, synthetic DNA or semisynthetic DNA. Among the polypeptide products which may be produced by the processes of this invention are, for - : :, :, :: ~ - , . ; , , , :., - . , , ~ . , , ~ . :
. . - . - . ~, ", , .
WO91/131~1 PCT/US91/01222 ~i,~SQ~
- ~5 -e~ample, coagulation factors VIII and IX, human or animal serum albumin, tissue plasminogen activator (tPA), urokinase, alpha-l antitrypsin, animal growth hormones, Mullerian Inhibiting Substance (MIS), cell S surface proteins, insulin, interferons, interleukins, milk lipases, antiviral proteins, peptide hormones, immunoglobulins, lipocortins and other heterologous protein products.
The desired heterologous polypeptide may be produced as a fusion protein containing amino acids in addition to those of the desired or native protein.
For example, the desired heterologous polypeptide of this invention may be produced as part of a larger heterologous protein or polypeptide in order to stabilize the desired protein or to make its purifi-cation easier and/or faster. This may be achieved by inserting the heterologous polypeptide encoding sequence into the island of expression at a position 5' to, and in reading frame with, the structural gene, or portion thereof, which was originally associated with the expression control sequences. It will ~e obvious that such a construct requires removal of the heterologous polypeptide termination codons prior to insertion into the island of expression.
Alternatively, the fusion protein coding region may be constructed prior to insertion into the island of expression. The fusion protein construct may comprise 2 or more heterologous polypeptide encoding sequences or portions therof, as long as the seqeunces are in the same reading frame. Such constructs may be made using techniques known in the art. The fusion protein may then be cleaved, if desired, and the desixed protein isolated. The desired heterologous polypeptide may be produced as a fragment or derivative of the polypeptide that was originally associated with .. - . . . . .................. . .
~: . .. ..
,., ~ . .
WO 91/1315t ` ~q rls~nl~ PJ' ~
the expression control sequences. Each of these alternatives is readily produced by merely choosing andtor manipulating the correct DNA sequences. Such manipulations are well known in the art.
The above-described island of expression constructs may be prepared using methods well known in the art. For example, various ligation techniques employing conventional linkers, restriction sites, etc.
may be used to good effect. Preferably, the islands of expression of this invention are prepared as part of larger plasmids. Such preparation allows the cloning and selection of the correct constructions in an efficient manner as is well known in the art and permits convenient production of large quantiti s of the island of expression construct.
The particular plasmid is not critical to the practice of this invention. Rather, any plasmid krlown in the art to be capable of being replicated, selected for, and carrying large pieces of DNA, would be a suitable vehicle in which to insert the islands of expression of this invention. Most preferably, the islands of expression of this invention are located between convenient restrictio~ sites on the plasmid so that they can be easily isolated from the remaining plasmid sequences for incorporation into the desired host.
The selection of an appropriate host for the island of expression invention is controlled by a number of factors recognized in the art. These include, for example, compatibility with the chosen vector, toxicity of the polypeptide products, ease of recovery of the desired heterologous polypeptide, expression characteristics, special processing requirements of the heterologous polypeptide, biosafety and costs. No absolute choice of host may be madejfor . : . . - : . , ............ .. : : .: ,:................ . :
: .: , . . ~ .... . . . : .. .
WO91~13151 z~5500 PCT/US91/012~2 .,;
~,,.,, : . . ;
., ,~ .
- 17;
a particular desired protein or polypeptide from any of these factors alone. Instead, a balance of these factors must be struck with the realization that not all hosts may be equally effective for expression of a particular heterologous polypeptide.
Useful mammalian host cells may include B and T lymphocytes, leukocytes, fibroblasts, hepatocytes, pancreatic cells and undifferentiated cells.
Preferably, immortalized mammalian cell lines would be utilized. For example, useful mammalian cell lines would include 3T3, 3T6, ST0, CH0, Ltk , FT02B, Hep2B, AR42J AND MPClL. Most preferable mammalian cell lines are CH0, 3T3, and Ltk .
Embryos from various mammals may be used in this invention to produce transgenic animals. The choice of a host embryo may depend on factors such as desired final destination of the heterologous polypeptide in the animal. For example, in a preferred embodiment for the expression of heterologous polypeptides in mammal's milk, preferred host embryos are from animals which are already bred for large volume milk production, e.g., cows, sheep, goats and pigs.
There are standard procedures for introducing the DNA of the expression construct into animal cells.
Commonly used transfection methods include electroporation tH. Potter et al., "Enhancer-Dependent Expression Of Human Kappa Immunoglobulin Genes Introduced Into Mouse Pre-B Lymhocytes By Electroporation", Proc. Natl. Acad. Sci. USA, 81(22), pp. 7161-65 (1984); G. Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient In Dihydrofolate Reductase Activity", Proc. Natl. Acad. Sci. USA, 77(7), pp. 4216-4200 (1980)], protoplast fusion [R.M. Sandri-Goldin et alO, Mol. Cell. Biol., l, pp. 743-52 (1981)], . . . ,~ , . .
. . : . . : : . , - . ~ . : , . . ............. .. .. .
. , . : . . . :
WO91/13151 ,~ PCT/US91/0122~ 1 ~ ,' t ~ 5V~ - 18 -calcium phosphate coprecipitation [F.L. Graham and A.J.
van der Eb, "A New Technique For The Assay of Infectivity Of Human Adenovirus 5 DNA", Viroloay, 52(2), pp. 456-67 (1973); A.D. Miller et al., "c-fos Protein Can Induce Cellular Transformation: A Novel Mechanism Of Activation Of A Cellular Oncogene", Cell, 36(1), pp. 51-60 (1981)] and DEAE-dextran sulfate mediated protocols. In addition, many variations of the DEAE-dextran sulfate and calcium phosphate methods exist [c. Queen and D. Baltimore, "Immunoglobulin Gene Transcription Is Activated By Downstream Sequence Elements", Cell, 33(3), pp. 741-48 (1983); C.M. Gorman et al., "Recombinant Genomes Which Express Chloramphenicol Acetyltransferase In Mammalian Cells", Mol. Cell. Biol., 2(9), pp. 1044-11 (1982); R.S. McIvor et al., "Expression Of A cDNA Sequence Encoding Human Purine Nucleoside Phosphorylase In Rodent And Human Cells", Mol. Cell. Biol., 5(6), pp. 1349-57 (1985)]
which may off~r certain advantages. For example, calcium phosphate coprecipitation procedures are particularly effective with mammalian cells, including CHO cells.
A selectable marker is usually cointroduced with the island of expression construct into mammalian cells as a separate piece of DNA so that those cells which incorporate the expression construct can be readily isolated. Useful selectable markers include dihydrofolate reductase, metallothionein, neo, ~Dt, and hisD among others. The selected c~lls are then tested for expression of the heterologous protein.
There are also standard techniques for introducing the expression construct into the genome of a mammalian embryo. One technique for transgenically altering a mammal is to microinject the island of expression construct into the pronucleus of the `i```` 2~55500 f ~ .
-- 19 -- , fertilized mammalian eggs to cause one or more copies of the construct to be integrated into the genome and retained in the cells of the developing mammals.
Briefly, microinjection involves isolating fertilized ova, visualizing the pronucleus and then injecting the DNA into the pronucleus by holding the ova with a blunt holding pipette (approximately 50 ~m in diameter) and using a sharply pointed pipet (approximately 1.5 ~m in diameter) to inject buffer containing DNA into the pronucleus. See, for example, D. Kraemer et al., "Gene Transfer Into Pronuclei Of Cattle And Sheep Zygotes", Genetic Mani~ulation of the Early Mammalian Embrvo, pp. 221-27, Cold Spring Harbor Laboratory (1985); R.E.
Hammer et al., "Production Of Transgenic Rabbits, Sheep And Pigs By Microinjection", Nature, 315, pp. 680-83 (1985); and J.W. Gordon and F.H. Ruddle, I'Gene Transfer Into Mouse Embryos: Production Of Transgenic Mice By Pronuclear Injection", Methods in EmbrYoloay, 101, pp. 411-33 (1983).
Microinjection is preferably carried out on an embryo at the one-cell stage, to maximize both the chances that the injected DNA will be incorporated into all cells of the animal and that the DNA will also be incorporated into the germ cells so that the animal's offspring will be transgenic as well. Usually, at least 40~ of the mammals developing from the injected eggs contain at least one copy of the cloned construct in somatic tissues and these "transgenic mammals"
usually transmit the gene through the germ line to the next generation. DNA isolated from the tissue of the resulting transgenic mammal may be tested for the presence of the island of expression by Southern blot analysis. If one or more copies of the island of expression remains stably integrated into the genome of such transgenic mammals, it is possible to establish :
. : . , -. . : , . , . . : ~ -.: . . .
WO91/131~1 PCT/US91/0122~ j Z ~555 o~ . A
permanent transgenic mammal lines carrying the island of expression construct.
The offspring of transgenically altered mammals may be assayed after birth for the incorporation of the island of expression construct into the genome. Preferably, this assay is accomplished by Southern hybridization of chromosomal material from the progeny using a probe corresponding to a portion of the heterologous polypeptide coding sequence. Those mammalian progeny found to contain at least one copy of the construct in their genome are grown to maturity. In a preferred embodiment of this invention, the female species of these progeny will produce the desired heterologous polypeptide in or along with their milk. Alternatively, the transgenic mammals may be bred to produce other transgenic progeny useful in producing the desired heterologous polypeptides.
EXAMPLES
S-l CASEIN ISLAND OF EXPRESSION
One example of this technology is to utilize the island of expression construct to produce a heterologous protein in a specific tissue or organ system of an intact animal. In this case we directed high level expression of a heterologous protein in the mammary gland of a mammal.
The gene construct described here contains an "island of expression" in which large 5' and 3' flanking regions of genomic sequence from the bovine alpha casein gene direct expression of the genomic clone of human urokinase. The 5' flanking region consists of 21 kb of upstream alpha casein sequences, including the first non-coding exon and the non-coding : , ~ , .
WOgl/l3l5l PCTtUS9ltO1222 ~`- 2~5550Q ` `
portion of the second exon. The 9 kb 3' flanking region consists of the exons encoding the COOH-terminal half of alpha casein, the polyadenylation signal, and 2 kb of further downstream flanking sequences.
We cloned the bovine alpha S-1 casein gene (CAS) from a cosmid library of calf thymus DNA in the cosmid vector HC79 (from Boehringer Mannheim) as described by B. Hohn and J. Collins, "A Small Cosmid For Efficient Cloning Of Large DNA Fragments", Gene, 11(3-4), pp. 291-98 (1980). The thymus was obtained from a slaughterhouse and the DNA isolated by standard techniques well known in the art (T. Maniatis et al., Molecular Cloning: A Laboratory Manual at page 271, Cold Spring Harbor Laboratory 1982)). We constructed the cosmid library using standard techniques (F.
Grosveld et al., "Isolation Of Beta - Globin - Related Genes From A Human Cosmid Library", Gene, 13(3), pp. 227-31 (1981)). We partially diqested the calf thymus DNA with Sau3A (New England Bio Labs) and ran it on a NaCl gradient (lM to 5M) to enrich for 30 to 40 kb fragments. The partially digested DNA fragments were then ligated into the BamHI digested HC79 cosmid vector, followed by in vitro packaging by lambda extracts (Amersham Corporation, Arlington Heights, IL) according to the manufacturer's instructions. The in vitro packaged material was then used to transfect the E.coli K-12 strain HB101. Clones incorporating this vector were selected by growth on LB plates containing 50 ~g/ml of Ampicillin (sigma Chemical Co., St. Louis MO)-We screened the resulting library using a 45base pair oligonucleotide probe, CAS-1. This CAS-l sequence, 5'-ATGGCTTGATCTTCAGTTGATTCACTCCCAATATCCTTGC
TCAG-3', was synthesized based upon a partial cDNA
sequence of alpha S-l casein described by I.M. Willis - - ~ . . . ~ , . -. - .
:.
': . ' :
. : . . 1.... :. . . .
., :- ~ . . . ~ . .
WO91/13151 PCT/US91/0122~
, ,~ "~ ~ , , ,1, r f et al., "Construction And Identifiction By Partial Nucleotide Sequence Analysis Of Bovine Casein And Beta-Lactoglobulin cDNA Clones", DNA, 1(4), pp. 375-86 (1982). This sequence corresponds to amino acids 20-35 of mature bovine casein. As a result of this screening, we isolated three clones containing cosmids (Cg, D4 and E1).
The 5' and 3' flanking sequences were obtained from cosmid clones, E1 and C9. Restriction mapping and Southern blot analysis (E. Southern, "Detection Of Specific Sequences Among DNA Fragments Separated By Gel Electrophoresis", J. Mol. Biol., 98 (3), pp. 503-517 (1975)) using oligonucleotide probes corresponding to known sequenced regions of the casein cDNA (A.F. Stewart et al., "~ucleotide Sequences Of Bovine Alpha S1- And Kappa-Casein cDNAs", Nucleic Acids Res., 12(9), pp. 3895-3907 (1984); M. Nagao et al., "Isolation And Sequence Analysis Of Bovine Alpha Sl-Casein cDNA Clone", Aqric. Biol. Chem., 48(6), pp. 1663-67 (1984)) established that cosmids D4 and El contained part of the casein structural gene (DNA
sequence coding for the casein protein) and 21 kb of upstream or 5' flanking sequences. The C9 cosmid contained part of the casein structural gene and extended to 7 kb downstream of the polyadenylation sequence. We sequenced the cosmids El and D4 in the ~ -region corresponding to the transcriptional start of the casein structural sequence and determined that the sequence corresponded to that of a published sequence of the same region. (L.Y. Yu-Lee et al., "Evolution Of The Casein Multigene Family: Conserved Seguences In The 5' Flanking And F.xon Regions", Nucleic Acid Res., 14(4), pp. 1883-1902 (1986)).
The construction of this island of expression in this invention is depicted in Figure 2. From the C9 . .
, .~ , . . . .......................... . .
. . , .. ., , , . ~ -.. - .
WO91/13151 PC~/US91/01222 2~555~
..
cosmid we subcloned the 9 kb BamHI fragment which begins at a BamHI site within the intron following amino acid # 98 of alpha casein and continues to another Bam site located 2 kb downstream of the polyadenyla~ion signal of alpha casein. This fragment is labelled as "C-term" in the Figure 2. This 9 kb fragment was cloned into BamHI-cut pUCl9 to yield pCAS947. The downstream BamHI site was converted to a SalI site by partial digestion of pCAS947 with BamHI
and subsequent ligation with a SaII linker, CAS lO, having the sequence, 5'-GATCGTCGAC-3'. The resulting plasmid was termed pCASl238. This 9 kb BamHI-SalI
fragment was used as the 3' flanking sequence of the "island". It contains the 3' untranslated region and 3' expression control sequences and a portion of the structural gene from alpha S-l casein.
The next step was to design the 5' flanking region. The region containing the transcriptional start, a non-coding exon and a second exon, part of which was also non-coding, was subcloned. A 4 kb SmaI/BamHI fragment from cosmid El was isolated and subcloned into BamHI/SmaI-cut pUCl9 to yield pCASl176. -The plasmid was cut with BalII, to remove the coding part of the second exon, and then the BalII site was converted to a BamHI site by ligation to a CAS 12 linker having the sequence, 5'-GATCTTGGATCCAA-3'. The resulting plasmid, pCASl181, was then digested with SmaI and BamHI to remove the 3 Xb piece of cosmid El DNA. The fragment was isolated, ligated to the 9 kb BamHI-SalI fragment from pCASl238, and inserted into the SmaI/SalI digested pUCl9 to yield pCASl276.
The resulting construct links the transcriptional start site to the downstream genomic sequence with a unique BamHI cloning site in between, into which the heterologous polypeptide encoding .
. . ; i , .
- , . . ~. ~ . -: ,'- , ' ' .` ,, :
- .
WO91/131~1 PCT/US91/01222 2~55~0(k~
sequence can be inserted. Since the final constructs will have several other BamHI sites in the genomic sequences, the heterologous polypeptide encoding sequence cloning site was changed to both an XhoI site and a NotI site by the addition of a linker, CAS 30, having the sequence, 5'-GATCTCGAGCGCGGCCGCGCT-3'. The resulting vector, pCASl277, contains XhoI and NotI
sites as cloning sites in between the transcriptional start of alpha casein and the C-terminal genomic portion of alpha casein.
The transcriptional start and C-term regions from pCASl277 were then used to replace the corresponding portions of the alpha casein genomic sequence found in the cosmid El. Since the construct is 39 kb in length, cosmid technology was used to manipulate the plasmids. The original El cosmid was partially digested with XmaI, followed by digestion to completion with SalI to remove the 3'- most portion of the alpha casein gene contained in that cosmid. The SmaI and XmaI enzymes have the same recognition site, except that XmaI leaves a 5' overhang whereas SmaI
leaves a blunt end. The 12 kb XmaI-SalI fragment from pCASl277 was then inserted into the XmaI/SalI-cut cosmid to replace the removed portion.
The ligated products were subjected to in vitro packaging using an in vitro packaging kit (Amersham Corporation) and the pac~aged DNA was used to transfect E.coli DH5 cells, followed by selection on LB
plates containing 50 ~g/ml of ampicillin (Sigma Chemical Co.). The plasmids from ampicillin-resistant colonies were screened using oligonucleotide probes specific for the 3' end of casein. We identified and characterized plasmids which contain 21 kb l~pstream of the transcriptional start and the XhoI/NotI cloning site along with the genomic 3' end of the casein gene.
WO91/13151 PCT/~S91/01222 ~; z~55SOO~ -One of these plasmids, CASl288, was then used to express the heterologous DNA sequence.
The qenomic clone of human urokinase was isolated from a genomic library using published sequences as probes. A. Riccio et al., suPra. From the published sequence, it can be seen that there is an ApaI site upstream of the translational start of the gene and also downstream of the polyA transcriptional signal. Oligonucleotide adapters (URO 8, having the sequence 5'-CGTCGACG-3', and URO 9, having the sequence 5'-GTACCGTCGACGGGCC-3') were used to add SalI sites to these two flanking ApaI sites. This allowed the genomic clone to be placed downstream of the SV40 early promoter in an animal cell expression vector so that we could test for expression prior to insertion in the alpha casein island of expression. The resulting plasmid, pUK0409, directed expression of authentic human urokinase in transfected tissue culture cells.
We therefore knew that the genomic clone was functional. The next step was to put the urokinase genomic clone into the XhoI cloning site of CASl288.
These steps are depicted in Figure 3.
The urokinase genomic clone was isolated as an 8 kb SalI fragment from pUK0409. The SalI
overhanging ends are capable of ligating into the XhoI
cloning site found in CASl288. There is, however, another XhoI site in the 21 kb upstream region of alpha casein. We therefore carried out partial XhoI
digestions, followed by ligation with the isolated SalI
urokinase fragment tsee Figure 3). Plasmids were isolated from-colonies and screened for the presence and orientation of the urokinase DNA sequence. One of these plasmids, CASl295, contained the uorkinase gene in the correct orientation as determined by restriction analysis. This plasmid contains in a 5'- to -3' - - . ~
WO91/13151 , ~,. PCT/US91/01222 ~`r ~
~ `:i;?
2C!55500 orientation, the 21 kb upstream region, the first non-coding exon and intron sequences of casein, the genomic sequence coding for urokinase, the 9 kb 3' genomic alpha casein region.
EXAMPLE 2 ~ TRANSGENIC INCORPORATION OF THE
IlISLAND OF EXPRESSION'I CONSTRUCT INTO MICE
In order to carry out transgenic experiments, the prokaryotic vector sequences present in CAS1295 were removed before injection into embryos. This was accomplished by digesting CAS1295 with ClaI and SalI, followed by gel electrophoresis in 1% agarose TBE (see Maniatis et al, supra). The 41 kb fragment corresponding to the eukaryotic sequences of the island of expression construct was cut out of the gel and the DNA isolated by electroelution. The DNA was then centrifuged overnight in an equilibrium CsCl gradient.
We removed the DNA band from the gradient and dialyzed extensively against TNE buffer (5 mM Tris, pH 7.4, 5 mM
NaCl and 0.1 mM EDTA, pH 8~.
The procedure for transgenic incorporation of the desired genetic information into the developing mouse embryo is established in the art. We followed t~chniques set forth in B. Hogan et al., Manipulatina The Mouse Embrvo: A Laboratorv Manual, Cold Spring Harbor Laboratory (1986). We used an F1 generation (Sloan Kettering) cross between C57B1 and CB6 mice (Jackson Laboratories). Six week old females were superovulated by injection of Gestile (pregnant mare serum) followed by human chorionic gonadotropin two days later. The treated females were bred with C57B1 stud males 24 hours later. The preimplantation fertilized embryos were removed within 12 hours following mating for microinjection with DNA and implantation into pseudopregnant females.
. . ........ .. . . .. . ... .. .. .... . . ..
,, . . ~ -, ~ . . . . . .
W09l/l3~5l Z~55500 PCl/~59l/~1~22 .'; ' .
After isolatir.g the embryo, we first digested away the cumulus cells surrounding the egg with hyaluronidase. The island of expression construct was then injected into the pronucleus of the embryo until it swelled 30% to 50% in size. We then implanted the injected embryos into the oviducts of pseudopregnant F1 females. DNA from the tails of the resulting live offspring was probed with nick translated CAS1295 DNA
to identify those animals which carried the island of expression contruct. Three transgenic animals were identified. These animals were mated and the progeny tested for the presence of the island of expression construct as described su~ra.
One of the transgenic lines, which carried 2-3 copies of the island of expression construct, passed the genetic material in a Mendelian manner. The females of this transgenic line, which carry the CAS1295 insert, all produce human urokinase in their milk at about 1 mg/ml, as determined by enzymatic assay. The urokinase is inhibited by the monoclonal antibody #394, specific for human uro~inase (Americana Diagnostica, Inc., New York, NY).
The other two transgenic lines carried 20-50 copies of the construct but failed to pass the DNA to the next generation of mice. We believe that the inability of the high copy number lines to pass the - genes is due to the high basal level of the urokinase during embryogenesis. Urokinase is normally expressed in fetal tissue (embryonic stem cells) and may function in development. The low basal level of urokinase expression from the casein expression control sequences would not interfere with development in those embryos inheriting two copies of the gene. However, if expression is dependent upon copy number, those lines ., , , ! . ; ' . . ~: ' . ' . ' . '., .. "' ~ .
', ' , ' '" , '' ' . " '' " ' , ~ ~ . ', '' ' .
WO 91/13~ f ~ ; PCT/US91/01222 , r ~ j .
:-~i .
~(~555~)0 which have 20-50 copies would have 20-50 fold higher basal level and would thereifore express enough urokinase to interfere with proper development. These results indicate that the level of urokinase expressed is copy number dependent.
EXPRESSION CONSTRUCT INTO ANIMAL CELLS
The island of expression construct and the the selectable marker pSV2-DHFR (available from the American Type Culture Collection (ATCC 37146)) which codes for the production of dihydrofolate reductase in mammalian cells, are cointroduced into DHFR CHO cells by electroporation. This technique is chosen for its ability to produce host cells characterized by stably integrated foreign DNA at high copy numbers. European Patent Application 0 343 783 fully describes this technique and is incorporated herein by reference.
Prior to electroporation, the pSV2-DHFR
plasmid is linearized by digestion overnight at 37C
with AatII. The island of expression seguences are isolated from the vector sequences by cutting with restriction enzymes as described in Example 2, followed by gel electrophoresis to allow separation and purification (Maniatis et al., supra). Salmon sperm DNA (200 ~g), previously sonicated to 300-1000 bp fragments, is added to a mixture containing 200 ~g sf the linearized pSV2-DHFR and 0.5 mg/ml of the island of expression construct. To precipitate the mixture of DNAs, NaCl is added to a final concentration of 0.1 M.
Next, 2.5 volumes of ethanol are added and the mixture is incubated for ten minutes on dry ice. After a ten minute centrifugation at 4C, the ethanol is aspirated and the DNA pellet is air-dried for 15 minutes in a tissue culture hood. The DNA pellet is then resuspended in 800 ~1 of lX HeBS (20 mM Hepes/NaOH, pH
.: . ,. . . i .
- : . , . :
WO9t/13151 PCT/US91/01222 ....
Z ~5~ .
, 7.05; 137 mM NaCl; S mM KCl; 0.7 mM Na~HP0,; 6mM
dextrose) for at least two hours prior to electroporation. 3 Approximately 2 x 107 DHFR CH0 cells (subcloned from the clone designated CH0-DUKX-Bl of Urlaub and Chasis, "Isolation Of Chinese Hamster Cell Mutants Deficient In Dihydrofolate Reductase Activity", Proc. Natl. Acas. Sci. UAS, 77, pp. 4216-20 (1980)) are used for each electroporation. The DHFR CH0 cells are passaged on the day prior to electoporation and are approximately 50% confluent on lO cm plates at the time of harvesting for electroporation. The DHFR CH0 cells are detached from the plates by trypsin treatment and the trypsin subsequently inactivated by the addition of 8.0 ml ~- medium (MEM alpha supplemented with ribonucleotides and deoxyribonucleotides ~lO mg/L each of adenosine, cytidine, guanosine, uridine, 2'-deoxyadenosine, 2'-deoxyguanosine and 2'-deoxy-thymidine; ll mg/L of 2'-deoxycytidine hydrochloride) (Gibco Laboratories, Grand Island, NY), 10% fetal bovine serum (Hazelton, Lenexa, RS) and 4 mM glutamine (M.A. Bioproducts, Walkersville, MD)) per plate. The cells detached from the plates are then collected and centrifuged at lO00 rpm for 4 minutes. The majority of the medium is aspirated off the cell pellet and the cells resuspended in the remaining residual media by flicking the tube.
The island of expression, pSV2-DHFR and salmon sperm DNA, suspended in 800 ~l lX HeBS, are then added to the DHFR CH0 cell suspension. Thz resulting mixture is immediately transferred to an electroporation cuvette. The capacitor of the electroporation apparatus is set at 960 ~F and the voltage set at 300V. A single pulse, lasting approximately lO milliseconds, is delivered to the .: : ' . . . ~ . . :' . , ' , '' ''., :
.: , ', :: , , ~ :
WO91/1315t PCT/US91/0122~ 1 2(~3;;,;;; ~ 1 contents of the cuvette at room temperature. The cells are then incu~ated for 8-lO minutes at room temperature and then transferred to a 15 ml tube containing 14 ml of ~ medium. The cells are centrifuged as above.
After aspirating the medium, the wet cell pellet is resuspended by flicking the tube and fresh ~+ medium is added. The suspended cells are then seeded into culture plates in non-selective medium for 2 days to allow them to recover from electroporation and express the selective gene. Approximately 20-30% of the viable CHO cells are expected to incorporate the island of -expression/pSV2-DHFR and thus survive the selection process. Therefore, approximately l x 107 total cells per lO cm plate are seeded and cultured in a 37C, 5.5%
C02 incubator.
After a recovery period of two days, the cells are removed from the culture plates by trypsin treatment as described above, counted and seeded into six lO cm plates at a density of about l x lo6 cells per plate, in ~ medium (Sigma Chemical Co.). The cells containing the island of expression and pSV2-DHFR are selected after a 4 day incubation in the ~~
media. The selected cells are then tested for expression of urokinase by standard techniques, e.g, a commercially available colorometric test, Spectrozyme UK (Americana Diagnostica, Inc.) Several clones that have various levels of expression of urokinase are selected. DNA and RNA are isolated from these clones and Northern and Southern analysis is carried out to determine transcription level and copy number of the island of expression construct. This analysis reveals whether expression of the uorkinase message is a function of the copy number and independent of the site of integration of the 3S integra~ed construct.
.. , , . ~ . ... . ..
A' .' ' ' . ' ; ~; '; ' ;;
WO9l/l3l~l PCT/US91/01222 ~, 2~sssoo t;~ '$," ' A construct according to this invention containing plasmid CAS1288 is exemplified by a culture deposited at In Vitro International, Inc. in Linthicum, Maryland, on February 1, 1990 and there identified as CAS1288 wherein the plasmid CAS1288 is in E.coli DH5.
It has been assigned accession number IVI 10232.
A second construct according to this invention containing plasmid CAS1295 is exemplified by a culture deposited at In Vitro International, Inc. in Linthicum, Maryland, on February 1, 1990 and there identified as CAS1295 wherein the plasmid CAS1295 is in E.coli DH5. It has been assigned accession number IVI
10231.
While we have hereinbefore presented a number of embodiments of our invention, it is apparent that our basic construction may be altered to provide other embodiments which utilize the processes and compositions of this invention. Therefore, it will be appreciated that the scope of this invention is to be 20 defined by the claims appended hereto, rather than the ::
specific embodiments which have been presented hereinbefore by way of example.
: :. ~ . . : . :
: . : , ~ . ~, :
IMPROVED EXPRESSION OF POLYPEPTIDES
TECHNICAL FIELD OF INVENTION
This invention relates to processes and intermediates for improving the level of production of a desired polypeptide in a recombinant host. More particularly, this invention relates to an "island of expression" -- a segment of DNA which contains a 3NA
sequence encoding a heterologous polypeptide -- and the use of the island of expression to transfect a host.
Hosts harboring this island of expression produce a surprisingly high level of the desired heterologous polypeptide. Incorporation of the island of expression - `
into a host permits the-desired heterologous polypeptide to be expressed substantially independent of its position of integration in the host genome and substantially dependent on the number of copies of the island of expression which integrate into the host genome.
BACKGROUND ART
It is well known that polypeptides can be expressed and secreted by hosts transformed or transfected with a DNA sequence coding for that polypeptide. For example, Gllbert et al., United States Patent 4,565,785 (1986) and L. Villa-Komaroff et al., "A Bacterial Clone Synthesizing Proinsulin", :'-- ., - . . .
~ . '" ' ' ' , . ~ . ', '. ' .
, ' ', .' ' ' . , ' WO 91/131~ i i PCT/US91/01~22 `I
2~5S500 Proc. Natl. Acad. Sci. USA, 75, pp. 3727-31 (1978) have shown that a selected polypeptide can be synthesized within a bacterial host and excreted through the host membrane. A similar process can be carried out in animal cells. J. Doehmer et al., "Introduction Of Rat Growth Hormone Gene Into Mouse Fibroblasts Via A
Retroviral DNA Vector: Expression And Regulation", Proc. Natl. Acad. Sci. USA, 79, pp. 2268-72 (1982).
Recombinant proteins have even been expressed in mammals through transgenic incorporation of an expression system into the pronucleus of a fertilized embryo. D. Bucchini et al., "Pancreatic Expression Of Human Insulin Gene In Transgenic Mice", Proc. Natl.
Acad. Sci. USA, 83, pp. 2511-15 (19863; K. Gordon et al., "Production Of Human Tissue Plasminogen Activator In Transgenic Mouse Milk", Bio/Technoloay, 5(11), pp. 1183-87 (1987).
However, to date, none of these techniques has been consistently successful in permitting large amounts of a desired heterologous polypeptide to be expressed by a host which has integrated into its genome a heterologous polypeptide encoding sequence.
This is particularly surprising in view of the high level of native protein production occasioned from the very same expression control sequences in their native environments. For example, milk specific expression control sequences permit large amounts of native proteins, e.g., casein, to be produced in and secreted from mammary glands. The very same milk specific expression control sequences, however, have not been demonstrated to induce large amounts of heterologous polypeptides when operatively linked to heterologous polypeptide encoding sequences. See, for example, C.W.
Pittius et al., "A Milk Protein Gene Promoter Directs The Expression Of Human Tissue Plasminogen Activator ., , .
WO9l/13151 2~55500 PCT/US91/01222 cDNA To T~e Mammary Gland In Transgenic Mice", Proc.
Natl. Acad. Sci. USA, 85, pp. 5874-78 (1988). The level of expression in these latter constructions is also independent of the number of copies of the heterologous polypeptide encoding sequence integrated into the host genome. Furthermore, the level of expression is subject to positional effects, i.e., it is dependent on where the heterologous polypeptide encoding sequence is integrated into the genome. K.F.
Lee et al., "Tissue-Specific Expression Of The Rat Beta-Casein Gene In Transgenic Mice", Nucleic Acids Res., 16(3), pp. 1027-41 (19 8).
Accordingly, the need exists for a method of increasing the expression of DNA sequence encoding a heterologous protein or polypeptide independent of its site of integration in the host genome. Moreover, such methods should provide expression that is dependent upon the number of copies integrated into the host genome so that expression levels may be controiled.
DISCLOSURE OF THE INVENTION
The present invention solves these problems by providing an "island of expression" containing a DNA
sequence which codes for a desired heterologous polypeptide. The island of expression of this invention provides for the first time, high level, position-independent and copy number-dependent expression of a DNA sequence coding for a heterologous polypeptide.
As is depicted in Figure 1, the island of expression of this invention comprises, in the 5' to 3' direction, a 5' flanking region, a heterologous -polypeptide encoding sequence ~coding for the desired heterologous protein or polypeptide) and a 3' flanking region. The 5' flanking region comprises,-in the 5' . . . ., . , : ............ . , :, .. , ., .. ., . :
. - : . . , : .: : . , ~ , -WO 91/t31~ 5 ~ ' ~ `? ~ PCT/US91/01222 and 3' direction, 5' expression control sequences and a 5' untranslated region. The expression control sequences are operatively linked to the heterologous polypeptide encoding sequence. The 5' untranslated region begins at a transcription initiation site and ends at the translational start site of the heterologous polypeptide encoding sequence. The 3' flanking region comprises in the 5' to 3' direction, a 3' untranslated region, and 3' expression control sequences, those control sequences being operatively linked to the heterologous polypeptide encoding sequence. Finally, the 5' and 3' flanking regions of the island of expression invention are characterized by a sufficient size and structure effective to render the level of production of the desired protein or polypeptide substantially dependent on the copy number of the island of expression integrated into the host genome and substantially independent of its integration site.
This invention also relates to the use of the island of expression to transfect a host and to those transfected hosts. Hosts which have integrated the island of expression into their genome produce high levels of the heterologous polypeptide encoded by a DNA
sequence within that island of expression.
Furthermore, the expression processes of this invention are substantially dependent on the copy number of the island of expression integrated into the host genome and independent of the site of integration, which advantageously allows expression levels to be manipulated.
In a preferred e~bodiment of this invention, the island of expression also includes a DNA sequence coding for a signal peptide. This signal sequence coding region is fused to, and in reading frame with, - , , ,:
. .
, . ,,, . . ., .- . .. . .
WO 91/131~t z~55500 PCI/VS91/01222 ~ .
~ I.t,~ !
the 5' end of the heterologous polypeptide coding sequence. The signal sequence coding region is also operatively linked to the expression control sequences so as to permit a host whose genome carries this preferred island of expression to produce, secrete, and preferably process, the desired protein or polypeptide from the pre-protein or pre-polypeptide coded for by the combined signal-heterologous polypeptide coding sequence.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts a schematic representation of a typical "island of expression" (A) and a preferred "island of expression" (B) in accordance with this invention.
Figure 2 depicts the construction of a plasmid (CAS1288) containing the 5' and 3' flanking regions of bovine alpha S-1 casein.
Figure 3 depic~s the introduction of the urokinase structural gene into CAS1288 to yield CAS1295, the island of expression.
DETAILED_DESCRIPTION OF THE INVENTION
In order that the invention herein described may be more fully understood, the following detailed description is set forth.
In this description the following terms are employed:
Expression controi sequences -- DNA sequences that control and r~gulate expression of gene products at both the transcriptional and translational level when operatively linked to a structural gene (DNA
coding for a polypeptide). They include the promoter and enhancer regions, ribosome binding sites, : . , . . . :, . . . . . . ............ . ........... :
: . . . . . . . . ... . . : , : . .
WO91/13151 ~ ! ' PCT/US91/01222 .~".
2~55500 ''`"
polyadenylation signals and other sequences useful in the expression of genes.
Operatively linked -- the linking of 5' and 3' expression control sequences to a heterologous polypeptide encoding sequence so as to permit the expression control sequences to control and regulate the expression and production of the heterologous polypeptide.
Heterologous polypeptide encoding sequence --a DNA sequence coding for a desired polypeptide orprotein that is inserted into the genome of a host.
This DNA sequence codes for a polypeptide which is heterologous to either the host, the flanking sequences or both. The heterologous polypeptide encoding sequence optionally contains its own translational start signal at its 5' end and its own translational stop codon at its 3' end. The heterologous polypeptide encoding sequence may also contain its own signal sequence coding region.
Signal sequence coding region -- a DNA
sequence which encodes a sequence of typically hydrophobic amino acids called a signal peptide. The signal peptide allows a polypeptide to which it is attached to cross a biological membrane.
Isiand of expression -- a DNA construct comprising in the 5' to 3' direction, a 5' flanking region, a heterologous polypeptide encoding sequence and a 3' flanking region. The S' and 3' flanking regions are of sufficient size and structure to render the level of production of the desired protein or polypeptide substantially dependent on the copy number of the island of expression construct incorporated into the host genome and substantially independent of the position of integration of the island of expression in the host genome.
.: . .. -- - . ~. - .. . , .. ., :
s .~ . . . . . . : . : - .
. :' . ~ ' '. : ,~ ' ; ' ' . ' : . . ; ' , ~ ' : .:, .: ' ., - ,, , : :
, ~ ~, ., -. ~ . : ' . :
~ ........................... 2(~SSSOO . .
~ i I J~
5' flanking region -- is that part of the island of expression which is 5' to the heterologous polypeptide encoding sequence. It includes, in the 5' to 3' direction, 5' expression control sequences and a 5' untranslated region, the expression control sequences being operatively linXed to the heterologous polypeptide encoding sequence. The 5' untranslated region typically extends from a transcription initiation site to the translational start site of the heterologous polypeptide encoding sequence.
3' flanking region -- is that part of the island of expression which is 3' to the heterologous polypeptide encoding sequence. It includes, in the 5' to 3' direction, a 3' untranslated region, and 3' expression control sequences. The 3' flanking region may also include all or a portion of the coding sequence from the structural gene originally associated with the 3' flanking region.
DETAILED DESCRIPTION OF THE INVENTION
Although not wishing to be bound by theory, we believe that the island of expression allows as yet undefined factors within the 5' and 3' flanking regions to operate on the expression control sequences and to permit the heterologous polypeptide encoding sequence to be expressed at higher yields. Expression is also dependent on the number of copies of the island of expression construct incorporated into the host genome, thus allowing the level of polypeptide production to be modulated.
The large 5' and 3' flanking regions of the islands of expression of this invention may also provide a buffer zone so that the expression control sequences are isolated from host expression controls which may be exerted by the surrounding DNA into which ' WO91/131~1 PCTtUS91/0~222 ,~ S ~! ~ t ~ t; ~
., ,~ ~' ', 2~5sSOO
the island of expression has integrated. Therefore, no matter where in the host genome the island of expression integrates, the heterolo~ous polypeptide encoding sequence will be expressed at a high level.
It carries its own genomic environment along with it, as an "island of expression".
Although not wishing to be bound by theory, we believe that the majority of regions of DNA which may enhance expression from expression control sequences are found in the 5' and 3' flanking sequences of a given structural gene. Therefore, after isolation of a structural gene with its 5' and 3' flanking regions, the structural gene, in accordance with one embodiment of this invention, may be excised in whole or in part and replaced with any heterologous polypeptide encoding ~e~uence so as to permit expression at a level consistent with that of the original structural gene. Alternatively, the heterologous polypeptide encoding sequence may be inserted at the 5' end of the structural gene without concomitant removal of that gene. In that embodiment, the heterologous polypeptide encoding sequence will also be expressed at a level that is comparable to the expression level of the original structural gene.
Among the expression control sequences useful in the various embodiments of this invention are those which direct expression at hi~h levels in particular types of cells or at particular stages of cell growth or differentiation, or under specific culture conditions. Tissue-specific expression control sequences are preferred in the transgenic hosts of this invention.
If mammalian host cells are utilized, useful expression control sequences may be derived from native sequences encoding a highly expressed product from the .. : , WO91/~31~1 PCT/US91/01222 ~` ` 2~SS~;~)O
g host cell itself, or they may be derived from other eukaryotic genes with high levels of expression, such as ~-actin, collagen, myosin, albumin, metallothionein and human growth hormone.
A preferred embodiment of this invention provides for the production of proteins in transgenic mammals. This embodiment preferably uses expression control sequences which control and direct expression of gene products in mammary tissue, such as expression control sequences corresponding to casein promoters and the beta lactoglobulin promoter. The casein promoters may, for example, be selected from an alpha casein promoter, a beta casein promoter or a kappa casein promoter. More preferably, the casein promoter and associated expression control sequences are of bovine oriqin and most preferably are an alpha S-l casein promoter and associated expression control sequences.
Expression control sequences may even be derived directly from the cells which are to be used as the host for the island of expression construct. A
promoter and associated expression control sequences having the desired level of activity in the host must first be identified. The island of expression must be designed so that each island of expression construct which integrates into the host genome is expressed in a copy number-dependent, position-independent manner.
We describe here a means of identifying expression control sequences, cloning the required flanking regions containing these sequences, adding the heterologous polypeptide encoding sequence, and testing whether the resultant construct is an "island of expression" in accordance with this invention.
The first step is to determine a host and conditions which allow a gene homologous to that host to be expressed at a desired level or at specific 21!55500 - lo -times. In the case of tissue culture, CH0 cells growing on the collagen beads found in the VERAX~
system are preferably used.
To isolate the expression control sequences for a homologous gene that is expressed at high levels in host cells under selected conditions, an abundantly expressed RNA species must be identified. This may be achieved by preparing a cDNA library from polyA RNA
isolated from a selected host cell under selected conditions of induction and growth. The cDNA library is then screened using ~ labelled aliquot of the same RNA from which the cDNA library was produced. The most positive signals are indicative of those cDNAs whose RNAs are most abundant in the host cell under the selected conditions of induction and growth. The selected cDNAs may then be used to screen genomic DNA
libraries prepared from the selected host cells in order to select genomic DNA sequences that correspond to most abundant RNAs. These genomic sequences, typically in cosmids [T. Mani~tis et al., Molecular Cloninq: A Laboratory Manual, Cold Spring Harbor Laboratory (1982)], may then be analyzed to determine restriction sites, the amount of flanking sequences in the cosmid and the polypeptide coding regions contained therein.
Alternatively, but less preferably, the expression control sequence may be isolated by screening a host cell grown under selected conditions and induction for an abundantly produced protein or polypeptide. This is achieved by analyzing the total polypeptides produced from the host using either SDS
polyacrylamide gel electrophoresis (SDS PAGE) or two-dimensional gel electrophoresis. The most abundant polypeptides are identified by the strongest band in an SDS-PAGE g~l or the largest spot in a two-dimensional .- ~' " ' . ; : , ~
WO91/131~1 PCT/US91/01222 `~``` 2(~55500 gel. Once identified, the band or spot is excised from the gel, eluted, and subjected to automated protein sequencing. Oligonucleotides based upon the amino acid sequence obtained from the protein sequencing are then synthesized. ~hese oligonucleotides can then be labeled and used as probes to identify their corresponding genomic sequences from a cosmid library constructed from host cell DNA.
Once a sufficiently detailed restriction map of this abundantly expressed gene has been determined, the coding sequences and intervening sequences of the structural gene may be removed from the cosmids, for example, with appropriate restriction enzymes and replaced with the heterologous polypeptide encoding sequence. Alternatively, the heterologous polypeptide encoding sequence may be inserted 5' to the structural gene. In this embodiment, the structural gene need not be excised. According to a preferred embodiment, the heterologous polypeptide is urokinase, the DNA sequence of which has been isolated and cloned from a genomic library using published sequences as probes. A. Riccio et al., "The Human Urokinase-Plasminogen Activator Gene And Its Promoter", Nucleic Acid Res., 13(8), pp. 2759-71 (1985).
The resulting construct has the DNA sequence coding for the heterologous polypeptide flanked on both sides by the genomic sequences of the abundantly expressed gene which was originally isolated from the host cells. Constructs containing the ~arious lengths of 5' and 3' flanking sequences must be tested to determine what size flanking regions are necessary to direct expression of the heterologous polypeptide encoding seguence in a copy number-dependent, position-independent manner.
.,--.. . . . . . ....................................... .
.. ; ... . .. . . . ..... . . . .
- : .: , . : . ,.
WO91/131~1 PCTIUS91/01222 I ~
2~S i~ 12 -To determine that the isolated cosmid contains sufficient 5' and 3' flanking regions to permit an inserted heterologous polypeptide encoding sequence to be expressed at substantially the same level as that of the highly expressed homologous DNA
sequence, the selected DNA sequence is transfected into cells in tissue culture or introduced into the genome of an embryos to produce transgenic animals.
Preferably, the cells or embryo that will be used for ultimate production are employed in this step. The transformed hosts are then tested for the expression of the heterologous protein by any of a number of well-known assays. These include, but are not limited to, radioimmunoassay, ELISA, immunoblotting and assays which measure the activity of the desired polypeptide.
Alternatively and preferably, mRNA levels under a variety of growth conditions are used. This may be achieved by the Northern blot technique using the previously described oligonucleotides (corresponding to the polypeptide sequences) or the cDNAs identified previously as probes.
Because the expression control sequences selected from the host cells demonstrate the ability to direct expression of the homologous gene at a high level under known conditions (e.g., CHO cells growing on collagen beads in the VERAX~ system), it is expected that substantially the same level of expression of the heterologous polypeptide would be seen under those same conditions. Should the cosmid derived DNA sequence not provide such level of expression, then other cosmids containing different lengths of 5' and 3' flanking regions should be analyzed in substantially the same way until an appropriate DNA sequence is located.
The levels of production of the heterologous protein adduced by this sequence are then compared to ,. . , . ~ . ., , ,; ~ , ; ~
WO9ltl3151 2~55500 PcT/US9l/01222 the copy numbers of the integrated island of expression. copy number is determined by appropriate restriction enzyme analysis. The expression constructs which show position-independent, copy number-dependent expression are the optimal "islands of expression" in accordance with this invention.
According to a preferred embodiment the desired polypeptide is secreted by a host harboring an island of expression of this invention. Secretion of polypeptides is accomplished by fusing a DNA sequence coding for a signal peptide to, and in reading frame with, the DNA encoding the heterologous polypeptide.
The size of the signal peptide is not critical for this invention. All that is required is that the signal peptide be of a sufficient size and sequence to effect secretion of the heterologous polypeptide. The signal sequence encoding the signal peptide may be exemplified by signal sequences associated in nature with the expression control sequences, signal sequences associated in nature with the desired heterologous protein or polypeptide, signal sequences which are native to the host, signal sequences which are native to the source of the heterologous polypeptide, signal sequences which are native to the source of the expression control sequences and any other sequences encoding functional signal peptides.
Many of the proteins to be expressed are normally secreted and will have their own signal peptide which should be adequate to direct secretionO
In this case, the DNA encoding that signal may be included in the heterologous polypeptide encoding sequence that is inserted into the island of expre~sion. To produce a polypeptide that is not normally secreted, it is possible to use a signal sequence from polypeptides which are normally secreted - . . ..
,.
W09l~l315l l ~ PCT/US91/01222 ~, ? ~ 't ~ 4 from the host cells or from other secreted polypeptides. A preferred embodiment of this invention uses sequences encoding milk-specific signal peptides or other signal peptides useful in the maturation and S secretion of protein in mammary tissue. These include the signal sequence from alpha S-1 casein. If the heterologous polypeptide to be expressed is associated in nature with its own signal sequence, the signal sequence associated in nature with the heterologous polypeptide coding sequence is the more preferred signal sequence.
The necessary 5' and 3' flanXing regions are characterized by the ability to cause expression from the island of expression construct to be position-independent and copy number-dependent. The length of the flanking sequences is not critical as long as these properties are conferred to the expression construct.
The upper size limit is defined by the ease of manipulating the DNA. In the original source of the expression control sequences (in the animal or in the cell line), the expression control sequences are flanked, in theory, by the whole chromosome. Present techniques allow the ready manipulation of 40-50 kb segments of DNA. This requires the use of well-known cosmid technology. There may also be a limit on the size of DNA that can be injected through the needles used in embryo manipulations. The preferred technique is to use as large 5' and 3' flanking regions as possible to insure enough insulating region to confer copy number dependence and position independence.
The coding sequence of the desired heterologous polypeptide can be derived from either cDNA, genomic sequences, synthetic DNA or semisynthetic DNA. Among the polypeptide products which may be produced by the processes of this invention are, for - : :, :, :: ~ - , . ; , , , :., - . , , ~ . , , ~ . :
. . - . - . ~, ", , .
WO91/131~1 PCT/US91/01222 ~i,~SQ~
- ~5 -e~ample, coagulation factors VIII and IX, human or animal serum albumin, tissue plasminogen activator (tPA), urokinase, alpha-l antitrypsin, animal growth hormones, Mullerian Inhibiting Substance (MIS), cell S surface proteins, insulin, interferons, interleukins, milk lipases, antiviral proteins, peptide hormones, immunoglobulins, lipocortins and other heterologous protein products.
The desired heterologous polypeptide may be produced as a fusion protein containing amino acids in addition to those of the desired or native protein.
For example, the desired heterologous polypeptide of this invention may be produced as part of a larger heterologous protein or polypeptide in order to stabilize the desired protein or to make its purifi-cation easier and/or faster. This may be achieved by inserting the heterologous polypeptide encoding sequence into the island of expression at a position 5' to, and in reading frame with, the structural gene, or portion thereof, which was originally associated with the expression control sequences. It will ~e obvious that such a construct requires removal of the heterologous polypeptide termination codons prior to insertion into the island of expression.
Alternatively, the fusion protein coding region may be constructed prior to insertion into the island of expression. The fusion protein construct may comprise 2 or more heterologous polypeptide encoding sequences or portions therof, as long as the seqeunces are in the same reading frame. Such constructs may be made using techniques known in the art. The fusion protein may then be cleaved, if desired, and the desixed protein isolated. The desired heterologous polypeptide may be produced as a fragment or derivative of the polypeptide that was originally associated with .. - . . . . .................. . .
~: . .. ..
,., ~ . .
WO 91/1315t ` ~q rls~nl~ PJ' ~
the expression control sequences. Each of these alternatives is readily produced by merely choosing andtor manipulating the correct DNA sequences. Such manipulations are well known in the art.
The above-described island of expression constructs may be prepared using methods well known in the art. For example, various ligation techniques employing conventional linkers, restriction sites, etc.
may be used to good effect. Preferably, the islands of expression of this invention are prepared as part of larger plasmids. Such preparation allows the cloning and selection of the correct constructions in an efficient manner as is well known in the art and permits convenient production of large quantiti s of the island of expression construct.
The particular plasmid is not critical to the practice of this invention. Rather, any plasmid krlown in the art to be capable of being replicated, selected for, and carrying large pieces of DNA, would be a suitable vehicle in which to insert the islands of expression of this invention. Most preferably, the islands of expression of this invention are located between convenient restrictio~ sites on the plasmid so that they can be easily isolated from the remaining plasmid sequences for incorporation into the desired host.
The selection of an appropriate host for the island of expression invention is controlled by a number of factors recognized in the art. These include, for example, compatibility with the chosen vector, toxicity of the polypeptide products, ease of recovery of the desired heterologous polypeptide, expression characteristics, special processing requirements of the heterologous polypeptide, biosafety and costs. No absolute choice of host may be madejfor . : . . - : . , ............ .. : : .: ,:................ . :
: .: , . . ~ .... . . . : .. .
WO91~13151 z~5500 PCT/US91/012~2 .,;
~,,.,, : . . ;
., ,~ .
- 17;
a particular desired protein or polypeptide from any of these factors alone. Instead, a balance of these factors must be struck with the realization that not all hosts may be equally effective for expression of a particular heterologous polypeptide.
Useful mammalian host cells may include B and T lymphocytes, leukocytes, fibroblasts, hepatocytes, pancreatic cells and undifferentiated cells.
Preferably, immortalized mammalian cell lines would be utilized. For example, useful mammalian cell lines would include 3T3, 3T6, ST0, CH0, Ltk , FT02B, Hep2B, AR42J AND MPClL. Most preferable mammalian cell lines are CH0, 3T3, and Ltk .
Embryos from various mammals may be used in this invention to produce transgenic animals. The choice of a host embryo may depend on factors such as desired final destination of the heterologous polypeptide in the animal. For example, in a preferred embodiment for the expression of heterologous polypeptides in mammal's milk, preferred host embryos are from animals which are already bred for large volume milk production, e.g., cows, sheep, goats and pigs.
There are standard procedures for introducing the DNA of the expression construct into animal cells.
Commonly used transfection methods include electroporation tH. Potter et al., "Enhancer-Dependent Expression Of Human Kappa Immunoglobulin Genes Introduced Into Mouse Pre-B Lymhocytes By Electroporation", Proc. Natl. Acad. Sci. USA, 81(22), pp. 7161-65 (1984); G. Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient In Dihydrofolate Reductase Activity", Proc. Natl. Acad. Sci. USA, 77(7), pp. 4216-4200 (1980)], protoplast fusion [R.M. Sandri-Goldin et alO, Mol. Cell. Biol., l, pp. 743-52 (1981)], . . . ,~ , . .
. . : . . : : . , - . ~ . : , . . ............. .. .. .
. , . : . . . :
WO91/13151 ,~ PCT/US91/0122~ 1 ~ ,' t ~ 5V~ - 18 -calcium phosphate coprecipitation [F.L. Graham and A.J.
van der Eb, "A New Technique For The Assay of Infectivity Of Human Adenovirus 5 DNA", Viroloay, 52(2), pp. 456-67 (1973); A.D. Miller et al., "c-fos Protein Can Induce Cellular Transformation: A Novel Mechanism Of Activation Of A Cellular Oncogene", Cell, 36(1), pp. 51-60 (1981)] and DEAE-dextran sulfate mediated protocols. In addition, many variations of the DEAE-dextran sulfate and calcium phosphate methods exist [c. Queen and D. Baltimore, "Immunoglobulin Gene Transcription Is Activated By Downstream Sequence Elements", Cell, 33(3), pp. 741-48 (1983); C.M. Gorman et al., "Recombinant Genomes Which Express Chloramphenicol Acetyltransferase In Mammalian Cells", Mol. Cell. Biol., 2(9), pp. 1044-11 (1982); R.S. McIvor et al., "Expression Of A cDNA Sequence Encoding Human Purine Nucleoside Phosphorylase In Rodent And Human Cells", Mol. Cell. Biol., 5(6), pp. 1349-57 (1985)]
which may off~r certain advantages. For example, calcium phosphate coprecipitation procedures are particularly effective with mammalian cells, including CHO cells.
A selectable marker is usually cointroduced with the island of expression construct into mammalian cells as a separate piece of DNA so that those cells which incorporate the expression construct can be readily isolated. Useful selectable markers include dihydrofolate reductase, metallothionein, neo, ~Dt, and hisD among others. The selected c~lls are then tested for expression of the heterologous protein.
There are also standard techniques for introducing the expression construct into the genome of a mammalian embryo. One technique for transgenically altering a mammal is to microinject the island of expression construct into the pronucleus of the `i```` 2~55500 f ~ .
-- 19 -- , fertilized mammalian eggs to cause one or more copies of the construct to be integrated into the genome and retained in the cells of the developing mammals.
Briefly, microinjection involves isolating fertilized ova, visualizing the pronucleus and then injecting the DNA into the pronucleus by holding the ova with a blunt holding pipette (approximately 50 ~m in diameter) and using a sharply pointed pipet (approximately 1.5 ~m in diameter) to inject buffer containing DNA into the pronucleus. See, for example, D. Kraemer et al., "Gene Transfer Into Pronuclei Of Cattle And Sheep Zygotes", Genetic Mani~ulation of the Early Mammalian Embrvo, pp. 221-27, Cold Spring Harbor Laboratory (1985); R.E.
Hammer et al., "Production Of Transgenic Rabbits, Sheep And Pigs By Microinjection", Nature, 315, pp. 680-83 (1985); and J.W. Gordon and F.H. Ruddle, I'Gene Transfer Into Mouse Embryos: Production Of Transgenic Mice By Pronuclear Injection", Methods in EmbrYoloay, 101, pp. 411-33 (1983).
Microinjection is preferably carried out on an embryo at the one-cell stage, to maximize both the chances that the injected DNA will be incorporated into all cells of the animal and that the DNA will also be incorporated into the germ cells so that the animal's offspring will be transgenic as well. Usually, at least 40~ of the mammals developing from the injected eggs contain at least one copy of the cloned construct in somatic tissues and these "transgenic mammals"
usually transmit the gene through the germ line to the next generation. DNA isolated from the tissue of the resulting transgenic mammal may be tested for the presence of the island of expression by Southern blot analysis. If one or more copies of the island of expression remains stably integrated into the genome of such transgenic mammals, it is possible to establish :
. : . , -. . : , . , . . : ~ -.: . . .
WO91/131~1 PCT/US91/0122~ j Z ~555 o~ . A
permanent transgenic mammal lines carrying the island of expression construct.
The offspring of transgenically altered mammals may be assayed after birth for the incorporation of the island of expression construct into the genome. Preferably, this assay is accomplished by Southern hybridization of chromosomal material from the progeny using a probe corresponding to a portion of the heterologous polypeptide coding sequence. Those mammalian progeny found to contain at least one copy of the construct in their genome are grown to maturity. In a preferred embodiment of this invention, the female species of these progeny will produce the desired heterologous polypeptide in or along with their milk. Alternatively, the transgenic mammals may be bred to produce other transgenic progeny useful in producing the desired heterologous polypeptides.
EXAMPLES
S-l CASEIN ISLAND OF EXPRESSION
One example of this technology is to utilize the island of expression construct to produce a heterologous protein in a specific tissue or organ system of an intact animal. In this case we directed high level expression of a heterologous protein in the mammary gland of a mammal.
The gene construct described here contains an "island of expression" in which large 5' and 3' flanking regions of genomic sequence from the bovine alpha casein gene direct expression of the genomic clone of human urokinase. The 5' flanking region consists of 21 kb of upstream alpha casein sequences, including the first non-coding exon and the non-coding : , ~ , .
WOgl/l3l5l PCTtUS9ltO1222 ~`- 2~5550Q ` `
portion of the second exon. The 9 kb 3' flanking region consists of the exons encoding the COOH-terminal half of alpha casein, the polyadenylation signal, and 2 kb of further downstream flanking sequences.
We cloned the bovine alpha S-1 casein gene (CAS) from a cosmid library of calf thymus DNA in the cosmid vector HC79 (from Boehringer Mannheim) as described by B. Hohn and J. Collins, "A Small Cosmid For Efficient Cloning Of Large DNA Fragments", Gene, 11(3-4), pp. 291-98 (1980). The thymus was obtained from a slaughterhouse and the DNA isolated by standard techniques well known in the art (T. Maniatis et al., Molecular Cloning: A Laboratory Manual at page 271, Cold Spring Harbor Laboratory 1982)). We constructed the cosmid library using standard techniques (F.
Grosveld et al., "Isolation Of Beta - Globin - Related Genes From A Human Cosmid Library", Gene, 13(3), pp. 227-31 (1981)). We partially diqested the calf thymus DNA with Sau3A (New England Bio Labs) and ran it on a NaCl gradient (lM to 5M) to enrich for 30 to 40 kb fragments. The partially digested DNA fragments were then ligated into the BamHI digested HC79 cosmid vector, followed by in vitro packaging by lambda extracts (Amersham Corporation, Arlington Heights, IL) according to the manufacturer's instructions. The in vitro packaged material was then used to transfect the E.coli K-12 strain HB101. Clones incorporating this vector were selected by growth on LB plates containing 50 ~g/ml of Ampicillin (sigma Chemical Co., St. Louis MO)-We screened the resulting library using a 45base pair oligonucleotide probe, CAS-1. This CAS-l sequence, 5'-ATGGCTTGATCTTCAGTTGATTCACTCCCAATATCCTTGC
TCAG-3', was synthesized based upon a partial cDNA
sequence of alpha S-l casein described by I.M. Willis - - ~ . . . ~ , . -. - .
:.
': . ' :
. : . . 1.... :. . . .
., :- ~ . . . ~ . .
WO91/13151 PCT/US91/0122~
, ,~ "~ ~ , , ,1, r f et al., "Construction And Identifiction By Partial Nucleotide Sequence Analysis Of Bovine Casein And Beta-Lactoglobulin cDNA Clones", DNA, 1(4), pp. 375-86 (1982). This sequence corresponds to amino acids 20-35 of mature bovine casein. As a result of this screening, we isolated three clones containing cosmids (Cg, D4 and E1).
The 5' and 3' flanking sequences were obtained from cosmid clones, E1 and C9. Restriction mapping and Southern blot analysis (E. Southern, "Detection Of Specific Sequences Among DNA Fragments Separated By Gel Electrophoresis", J. Mol. Biol., 98 (3), pp. 503-517 (1975)) using oligonucleotide probes corresponding to known sequenced regions of the casein cDNA (A.F. Stewart et al., "~ucleotide Sequences Of Bovine Alpha S1- And Kappa-Casein cDNAs", Nucleic Acids Res., 12(9), pp. 3895-3907 (1984); M. Nagao et al., "Isolation And Sequence Analysis Of Bovine Alpha Sl-Casein cDNA Clone", Aqric. Biol. Chem., 48(6), pp. 1663-67 (1984)) established that cosmids D4 and El contained part of the casein structural gene (DNA
sequence coding for the casein protein) and 21 kb of upstream or 5' flanking sequences. The C9 cosmid contained part of the casein structural gene and extended to 7 kb downstream of the polyadenylation sequence. We sequenced the cosmids El and D4 in the ~ -region corresponding to the transcriptional start of the casein structural sequence and determined that the sequence corresponded to that of a published sequence of the same region. (L.Y. Yu-Lee et al., "Evolution Of The Casein Multigene Family: Conserved Seguences In The 5' Flanking And F.xon Regions", Nucleic Acid Res., 14(4), pp. 1883-1902 (1986)).
The construction of this island of expression in this invention is depicted in Figure 2. From the C9 . .
, .~ , . . . .......................... . .
. . , .. ., , , . ~ -.. - .
WO91/13151 PC~/US91/01222 2~555~
..
cosmid we subcloned the 9 kb BamHI fragment which begins at a BamHI site within the intron following amino acid # 98 of alpha casein and continues to another Bam site located 2 kb downstream of the polyadenyla~ion signal of alpha casein. This fragment is labelled as "C-term" in the Figure 2. This 9 kb fragment was cloned into BamHI-cut pUCl9 to yield pCAS947. The downstream BamHI site was converted to a SalI site by partial digestion of pCAS947 with BamHI
and subsequent ligation with a SaII linker, CAS lO, having the sequence, 5'-GATCGTCGAC-3'. The resulting plasmid was termed pCASl238. This 9 kb BamHI-SalI
fragment was used as the 3' flanking sequence of the "island". It contains the 3' untranslated region and 3' expression control sequences and a portion of the structural gene from alpha S-l casein.
The next step was to design the 5' flanking region. The region containing the transcriptional start, a non-coding exon and a second exon, part of which was also non-coding, was subcloned. A 4 kb SmaI/BamHI fragment from cosmid El was isolated and subcloned into BamHI/SmaI-cut pUCl9 to yield pCASl176. -The plasmid was cut with BalII, to remove the coding part of the second exon, and then the BalII site was converted to a BamHI site by ligation to a CAS 12 linker having the sequence, 5'-GATCTTGGATCCAA-3'. The resulting plasmid, pCASl181, was then digested with SmaI and BamHI to remove the 3 Xb piece of cosmid El DNA. The fragment was isolated, ligated to the 9 kb BamHI-SalI fragment from pCASl238, and inserted into the SmaI/SalI digested pUCl9 to yield pCASl276.
The resulting construct links the transcriptional start site to the downstream genomic sequence with a unique BamHI cloning site in between, into which the heterologous polypeptide encoding .
. . ; i , .
- , . . ~. ~ . -: ,'- , ' ' .` ,, :
- .
WO91/131~1 PCT/US91/01222 2~55~0(k~
sequence can be inserted. Since the final constructs will have several other BamHI sites in the genomic sequences, the heterologous polypeptide encoding sequence cloning site was changed to both an XhoI site and a NotI site by the addition of a linker, CAS 30, having the sequence, 5'-GATCTCGAGCGCGGCCGCGCT-3'. The resulting vector, pCASl277, contains XhoI and NotI
sites as cloning sites in between the transcriptional start of alpha casein and the C-terminal genomic portion of alpha casein.
The transcriptional start and C-term regions from pCASl277 were then used to replace the corresponding portions of the alpha casein genomic sequence found in the cosmid El. Since the construct is 39 kb in length, cosmid technology was used to manipulate the plasmids. The original El cosmid was partially digested with XmaI, followed by digestion to completion with SalI to remove the 3'- most portion of the alpha casein gene contained in that cosmid. The SmaI and XmaI enzymes have the same recognition site, except that XmaI leaves a 5' overhang whereas SmaI
leaves a blunt end. The 12 kb XmaI-SalI fragment from pCASl277 was then inserted into the XmaI/SalI-cut cosmid to replace the removed portion.
The ligated products were subjected to in vitro packaging using an in vitro packaging kit (Amersham Corporation) and the pac~aged DNA was used to transfect E.coli DH5 cells, followed by selection on LB
plates containing 50 ~g/ml of ampicillin (Sigma Chemical Co.). The plasmids from ampicillin-resistant colonies were screened using oligonucleotide probes specific for the 3' end of casein. We identified and characterized plasmids which contain 21 kb l~pstream of the transcriptional start and the XhoI/NotI cloning site along with the genomic 3' end of the casein gene.
WO91/13151 PCT/~S91/01222 ~; z~55SOO~ -One of these plasmids, CASl288, was then used to express the heterologous DNA sequence.
The qenomic clone of human urokinase was isolated from a genomic library using published sequences as probes. A. Riccio et al., suPra. From the published sequence, it can be seen that there is an ApaI site upstream of the translational start of the gene and also downstream of the polyA transcriptional signal. Oligonucleotide adapters (URO 8, having the sequence 5'-CGTCGACG-3', and URO 9, having the sequence 5'-GTACCGTCGACGGGCC-3') were used to add SalI sites to these two flanking ApaI sites. This allowed the genomic clone to be placed downstream of the SV40 early promoter in an animal cell expression vector so that we could test for expression prior to insertion in the alpha casein island of expression. The resulting plasmid, pUK0409, directed expression of authentic human urokinase in transfected tissue culture cells.
We therefore knew that the genomic clone was functional. The next step was to put the urokinase genomic clone into the XhoI cloning site of CASl288.
These steps are depicted in Figure 3.
The urokinase genomic clone was isolated as an 8 kb SalI fragment from pUK0409. The SalI
overhanging ends are capable of ligating into the XhoI
cloning site found in CASl288. There is, however, another XhoI site in the 21 kb upstream region of alpha casein. We therefore carried out partial XhoI
digestions, followed by ligation with the isolated SalI
urokinase fragment tsee Figure 3). Plasmids were isolated from-colonies and screened for the presence and orientation of the urokinase DNA sequence. One of these plasmids, CASl295, contained the uorkinase gene in the correct orientation as determined by restriction analysis. This plasmid contains in a 5'- to -3' - - . ~
WO91/13151 , ~,. PCT/US91/01222 ~`r ~
~ `:i;?
2C!55500 orientation, the 21 kb upstream region, the first non-coding exon and intron sequences of casein, the genomic sequence coding for urokinase, the 9 kb 3' genomic alpha casein region.
EXAMPLE 2 ~ TRANSGENIC INCORPORATION OF THE
IlISLAND OF EXPRESSION'I CONSTRUCT INTO MICE
In order to carry out transgenic experiments, the prokaryotic vector sequences present in CAS1295 were removed before injection into embryos. This was accomplished by digesting CAS1295 with ClaI and SalI, followed by gel electrophoresis in 1% agarose TBE (see Maniatis et al, supra). The 41 kb fragment corresponding to the eukaryotic sequences of the island of expression construct was cut out of the gel and the DNA isolated by electroelution. The DNA was then centrifuged overnight in an equilibrium CsCl gradient.
We removed the DNA band from the gradient and dialyzed extensively against TNE buffer (5 mM Tris, pH 7.4, 5 mM
NaCl and 0.1 mM EDTA, pH 8~.
The procedure for transgenic incorporation of the desired genetic information into the developing mouse embryo is established in the art. We followed t~chniques set forth in B. Hogan et al., Manipulatina The Mouse Embrvo: A Laboratorv Manual, Cold Spring Harbor Laboratory (1986). We used an F1 generation (Sloan Kettering) cross between C57B1 and CB6 mice (Jackson Laboratories). Six week old females were superovulated by injection of Gestile (pregnant mare serum) followed by human chorionic gonadotropin two days later. The treated females were bred with C57B1 stud males 24 hours later. The preimplantation fertilized embryos were removed within 12 hours following mating for microinjection with DNA and implantation into pseudopregnant females.
. . ........ .. . . .. . ... .. .. .... . . ..
,, . . ~ -, ~ . . . . . .
W09l/l3~5l Z~55500 PCl/~59l/~1~22 .'; ' .
After isolatir.g the embryo, we first digested away the cumulus cells surrounding the egg with hyaluronidase. The island of expression construct was then injected into the pronucleus of the embryo until it swelled 30% to 50% in size. We then implanted the injected embryos into the oviducts of pseudopregnant F1 females. DNA from the tails of the resulting live offspring was probed with nick translated CAS1295 DNA
to identify those animals which carried the island of expression contruct. Three transgenic animals were identified. These animals were mated and the progeny tested for the presence of the island of expression construct as described su~ra.
One of the transgenic lines, which carried 2-3 copies of the island of expression construct, passed the genetic material in a Mendelian manner. The females of this transgenic line, which carry the CAS1295 insert, all produce human urokinase in their milk at about 1 mg/ml, as determined by enzymatic assay. The urokinase is inhibited by the monoclonal antibody #394, specific for human uro~inase (Americana Diagnostica, Inc., New York, NY).
The other two transgenic lines carried 20-50 copies of the construct but failed to pass the DNA to the next generation of mice. We believe that the inability of the high copy number lines to pass the - genes is due to the high basal level of the urokinase during embryogenesis. Urokinase is normally expressed in fetal tissue (embryonic stem cells) and may function in development. The low basal level of urokinase expression from the casein expression control sequences would not interfere with development in those embryos inheriting two copies of the gene. However, if expression is dependent upon copy number, those lines ., , , ! . ; ' . . ~: ' . ' . ' . '., .. "' ~ .
', ' , ' '" , '' ' . " '' " ' , ~ ~ . ', '' ' .
WO 91/13~ f ~ ; PCT/US91/01222 , r ~ j .
:-~i .
~(~555~)0 which have 20-50 copies would have 20-50 fold higher basal level and would thereifore express enough urokinase to interfere with proper development. These results indicate that the level of urokinase expressed is copy number dependent.
EXPRESSION CONSTRUCT INTO ANIMAL CELLS
The island of expression construct and the the selectable marker pSV2-DHFR (available from the American Type Culture Collection (ATCC 37146)) which codes for the production of dihydrofolate reductase in mammalian cells, are cointroduced into DHFR CHO cells by electroporation. This technique is chosen for its ability to produce host cells characterized by stably integrated foreign DNA at high copy numbers. European Patent Application 0 343 783 fully describes this technique and is incorporated herein by reference.
Prior to electroporation, the pSV2-DHFR
plasmid is linearized by digestion overnight at 37C
with AatII. The island of expression seguences are isolated from the vector sequences by cutting with restriction enzymes as described in Example 2, followed by gel electrophoresis to allow separation and purification (Maniatis et al., supra). Salmon sperm DNA (200 ~g), previously sonicated to 300-1000 bp fragments, is added to a mixture containing 200 ~g sf the linearized pSV2-DHFR and 0.5 mg/ml of the island of expression construct. To precipitate the mixture of DNAs, NaCl is added to a final concentration of 0.1 M.
Next, 2.5 volumes of ethanol are added and the mixture is incubated for ten minutes on dry ice. After a ten minute centrifugation at 4C, the ethanol is aspirated and the DNA pellet is air-dried for 15 minutes in a tissue culture hood. The DNA pellet is then resuspended in 800 ~1 of lX HeBS (20 mM Hepes/NaOH, pH
.: . ,. . . i .
- : . , . :
WO9t/13151 PCT/US91/01222 ....
Z ~5~ .
, 7.05; 137 mM NaCl; S mM KCl; 0.7 mM Na~HP0,; 6mM
dextrose) for at least two hours prior to electroporation. 3 Approximately 2 x 107 DHFR CH0 cells (subcloned from the clone designated CH0-DUKX-Bl of Urlaub and Chasis, "Isolation Of Chinese Hamster Cell Mutants Deficient In Dihydrofolate Reductase Activity", Proc. Natl. Acas. Sci. UAS, 77, pp. 4216-20 (1980)) are used for each electroporation. The DHFR CH0 cells are passaged on the day prior to electoporation and are approximately 50% confluent on lO cm plates at the time of harvesting for electroporation. The DHFR CH0 cells are detached from the plates by trypsin treatment and the trypsin subsequently inactivated by the addition of 8.0 ml ~- medium (MEM alpha supplemented with ribonucleotides and deoxyribonucleotides ~lO mg/L each of adenosine, cytidine, guanosine, uridine, 2'-deoxyadenosine, 2'-deoxyguanosine and 2'-deoxy-thymidine; ll mg/L of 2'-deoxycytidine hydrochloride) (Gibco Laboratories, Grand Island, NY), 10% fetal bovine serum (Hazelton, Lenexa, RS) and 4 mM glutamine (M.A. Bioproducts, Walkersville, MD)) per plate. The cells detached from the plates are then collected and centrifuged at lO00 rpm for 4 minutes. The majority of the medium is aspirated off the cell pellet and the cells resuspended in the remaining residual media by flicking the tube.
The island of expression, pSV2-DHFR and salmon sperm DNA, suspended in 800 ~l lX HeBS, are then added to the DHFR CH0 cell suspension. Thz resulting mixture is immediately transferred to an electroporation cuvette. The capacitor of the electroporation apparatus is set at 960 ~F and the voltage set at 300V. A single pulse, lasting approximately lO milliseconds, is delivered to the .: : ' . . . ~ . . :' . , ' , '' ''., :
.: , ', :: , , ~ :
WO91/1315t PCT/US91/0122~ 1 2(~3;;,;;; ~ 1 contents of the cuvette at room temperature. The cells are then incu~ated for 8-lO minutes at room temperature and then transferred to a 15 ml tube containing 14 ml of ~ medium. The cells are centrifuged as above.
After aspirating the medium, the wet cell pellet is resuspended by flicking the tube and fresh ~+ medium is added. The suspended cells are then seeded into culture plates in non-selective medium for 2 days to allow them to recover from electroporation and express the selective gene. Approximately 20-30% of the viable CHO cells are expected to incorporate the island of -expression/pSV2-DHFR and thus survive the selection process. Therefore, approximately l x 107 total cells per lO cm plate are seeded and cultured in a 37C, 5.5%
C02 incubator.
After a recovery period of two days, the cells are removed from the culture plates by trypsin treatment as described above, counted and seeded into six lO cm plates at a density of about l x lo6 cells per plate, in ~ medium (Sigma Chemical Co.). The cells containing the island of expression and pSV2-DHFR are selected after a 4 day incubation in the ~~
media. The selected cells are then tested for expression of urokinase by standard techniques, e.g, a commercially available colorometric test, Spectrozyme UK (Americana Diagnostica, Inc.) Several clones that have various levels of expression of urokinase are selected. DNA and RNA are isolated from these clones and Northern and Southern analysis is carried out to determine transcription level and copy number of the island of expression construct. This analysis reveals whether expression of the uorkinase message is a function of the copy number and independent of the site of integration of the 3S integra~ed construct.
.. , , . ~ . ... . ..
A' .' ' ' . ' ; ~; '; ' ;;
WO9l/l3l~l PCT/US91/01222 ~, 2~sssoo t;~ '$," ' A construct according to this invention containing plasmid CAS1288 is exemplified by a culture deposited at In Vitro International, Inc. in Linthicum, Maryland, on February 1, 1990 and there identified as CAS1288 wherein the plasmid CAS1288 is in E.coli DH5.
It has been assigned accession number IVI 10232.
A second construct according to this invention containing plasmid CAS1295 is exemplified by a culture deposited at In Vitro International, Inc. in Linthicum, Maryland, on February 1, 1990 and there identified as CAS1295 wherein the plasmid CAS1295 is in E.coli DH5. It has been assigned accession number IVI
10231.
While we have hereinbefore presented a number of embodiments of our invention, it is apparent that our basic construction may be altered to provide other embodiments which utilize the processes and compositions of this invention. Therefore, it will be appreciated that the scope of this invention is to be 20 defined by the claims appended hereto, rather than the ::
specific embodiments which have been presented hereinbefore by way of example.
: :. ~ . . : . :
: . : , ~ . ~, :
Claims (13)
1. A process for producing a high the level of a desired heterologous polypeptide in a host, the process comprising the steps of:
a) integrating at least one island of expression into the genome of said host, wherein said island of expression comprises, in the 5' to 3' direction, a 5' flanking region, a heterologous polypeptide encoding sequence and a 3' flanking region;
said 5' flanking region comprising 5' expression control sequences, operatively linked to said heterologous polypeptide encoding sequence and a 5' untranslated region; said 3' flanking region comprising, a 3' untranslated region, and 3' expression control sequences, operatively linked to said heterologous polypeptide encoding sequence; and the 5' and 3' flanking regions of said islands of expression being of sufficient size and structure effective to render the level of production of the desired heterologous polypeptide substantially dependent on the copy number of the island of expression integrated into the host genome and substantially independent of the position of integration of the island of expression in the host genome; and b) culturing said host under conditions which allow said desired heterologous polypeptide to be expressed.
a) integrating at least one island of expression into the genome of said host, wherein said island of expression comprises, in the 5' to 3' direction, a 5' flanking region, a heterologous polypeptide encoding sequence and a 3' flanking region;
said 5' flanking region comprising 5' expression control sequences, operatively linked to said heterologous polypeptide encoding sequence and a 5' untranslated region; said 3' flanking region comprising, a 3' untranslated region, and 3' expression control sequences, operatively linked to said heterologous polypeptide encoding sequence; and the 5' and 3' flanking regions of said islands of expression being of sufficient size and structure effective to render the level of production of the desired heterologous polypeptide substantially dependent on the copy number of the island of expression integrated into the host genome and substantially independent of the position of integration of the island of expression in the host genome; and b) culturing said host under conditions which allow said desired heterologous polypeptide to be expressed.
2. The process according to claim 1 wherein said heterologous polypeptide encoding sequence comprises a functional signal sequence coding region.
3. The process according to claim 2 wherein the signal sequence coding region is derived from a milk specific protein gene.
4. The process according to claim 3 wherein the milk specific protein gene is casein.
5. The process according to any one of claims 2 to 4 wherein the host is a lactating mammal selected from the group consisting of mice, cows, sheep, goats and pigs and the 5' and 3' flanking sequences are derived from a milk specific protein gene.
6. The process according to claim 1 wherein the heterologous polypeptide encoding sequence is selected from sequences encoding a polypeptide selected from the group consisting of: tPA, urokinase, Mullerian Inhibiting Substance, interferons, coagulation factors VIII and IX, animal growth hormones, insulin, interleukins, immunoglobulins and lipocortins.
7. An island of expression DNA sequence comprising, in the 5' to 3' direction, a 5' flanking region, a heterologous polypeptide encoding sequence and a 3' flanking region; the 5' flanking region comprising 5' expression control sequences operatively linked to the heterologous polypeptide encoding sequence and a 5' untranslated region; the 3' flanking region comprising a 3' untranslated region, and 3' expression control sequences, operatively linked to the heterologous polypeptide encoding region; whereinupon the integration of the island of expression into the genome of a host, the 5' and 3' flanking regions of the island of expression are of sufficient size and structure effective to render a level of production of a polypeptide encoded by the heterologous polypeptide encoding sequence substantially dependent on the copy number of the island of expression in the host genome and substantially independent of the position of integration of the island of expression in the host genome.
8. The island of expression according to claim 7 wherein the heterologous polypeptide encoding sequence comprises a functional signal sequence coding region.
9. The island of expression according to claim 7 wherein the 5' and 3' flanking sequences are derived from a milk specific protein gene.
10. The island of expression according to claim 8 wherein the signal sequence coding region is derived from a milk specific protein gene.
11. The island of expression according to claim 9 wherein the milk specific protein gene is casein.
12. The island of expression according to claim 7 wherein the heterologous polypeptide encoding sequence is selected from sequences encoding a polypeptide selected from the group consisting of: tPA, urokinase, Mullerian Inhibiting Substance, interferons, coagulation factors VIII and IX, animal growth hormones, insulin, interleukins, immunoglobulins and lipocortins.
13. A transformed host characterized by a genome comprising an integrated island of expression, said island of expression according to any one of claims 7 to 12.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48345090A | 1990-02-22 | 1990-02-22 | |
US483,450 | 1990-02-22 | ||
PCT/US1991/001222 WO1991013151A1 (en) | 1990-02-22 | 1991-02-22 | Improved expression of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2055500A1 true CA2055500A1 (en) | 1991-08-23 |
Family
ID=23920077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002055500A Abandoned CA2055500A1 (en) | 1990-02-22 | 1991-02-22 | Expression of polypeptides |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0471832A1 (en) |
JP (1) | JPH04505710A (en) |
AU (1) | AU652355B2 (en) |
CA (1) | CA2055500A1 (en) |
FI (1) | FI914947A0 (en) |
HU (1) | HUT60523A (en) |
WO (1) | WO1991013151A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
GB9027917D0 (en) * | 1990-12-21 | 1991-02-13 | Ici Plc | Expression systems |
GB9028062D0 (en) * | 1990-12-24 | 1991-02-13 | Agricultural & Food Res | Production of transgenic animals |
US5714345A (en) * | 1990-12-24 | 1998-02-03 | Pharmaceutical Proteins Limited | Increased expression of a gene by a second transferred mammary gland specific sequence transgenic |
US5733761A (en) * | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US6054288A (en) * | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6692737B1 (en) | 1991-11-05 | 2004-02-17 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US6063630A (en) * | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
PT101031B (en) * | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US6531124B1 (en) | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
US6670178B1 (en) | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
US5959171A (en) * | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
JP3240370B2 (en) * | 1997-01-17 | 2001-12-17 | 農林水産省畜産試験場長 | Method for introducing foreign gene into cultured cells or fertilized eggs |
GB9718908D0 (en) | 1997-09-05 | 1997-11-12 | Rowett Research Services Limit | Proteins |
GB0314856D0 (en) | 2003-06-25 | 2003-07-30 | Unitargeting Res As | Protein expression system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
GB8718779D0 (en) * | 1987-08-07 | 1987-09-16 | Grosveld F G | Dna sequence & expression vector |
AU622870B2 (en) * | 1987-08-07 | 1992-04-30 | Medical Research Council, The | Vector for integration site independent gene expression in mammalian host cells |
-
1991
- 1991-02-22 WO PCT/US1991/001222 patent/WO1991013151A1/en not_active Application Discontinuation
- 1991-02-22 HU HU364891A patent/HUT60523A/en unknown
- 1991-02-22 JP JP50601791A patent/JPH04505710A/en active Pending
- 1991-02-22 CA CA002055500A patent/CA2055500A1/en not_active Abandoned
- 1991-02-22 AU AU74863/91A patent/AU652355B2/en not_active Ceased
- 1991-02-22 EP EP19910906376 patent/EP0471832A1/en not_active Withdrawn
- 1991-10-21 FI FI914947A patent/FI914947A0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUT60523A (en) | 1992-09-28 |
HU913648D0 (en) | 1992-07-28 |
AU652355B2 (en) | 1994-08-25 |
WO1991013151A1 (en) | 1991-09-05 |
AU7486391A (en) | 1991-09-18 |
JPH04505710A (en) | 1992-10-08 |
FI914947A0 (en) | 1991-10-21 |
EP0471832A1 (en) | 1992-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4873316A (en) | Isolation of exogenous recombinant proteins from the milk of transgenic mammals | |
US5750172A (en) | Transgenic non human mammal milk | |
Meade et al. | Bovine alphas1-casein gene sequences direct high level expression of active human urokinase in mouse milk | |
AU652355B2 (en) | Improved expression of polypeptides | |
CA1321764C (en) | Dna sequence to target proteins to the mammary gland for efficient secretion | |
US7045676B1 (en) | Transgenic animals secreting proteins into milk | |
JPH10506013A (en) | Transgenic animals expressing human coagulation factor VIII and von Willebrand factor | |
WO1988001648A1 (en) | Expression of heterologous proteins by transgenic lactating mammals | |
US5648243A (en) | Human serum albumin expression construct | |
JPH04365487A (en) | Recombinant dna structure, recombinant vector, method for obtaining protein from milk of transgenic animal, method for producing transgenic animal and milk of transgenic animal | |
EP0771874B1 (en) | Transgenic protein production | |
KR20070081531A (en) | Mammary gland-specific human erythropoietin expression vector, transgenic animal and method for producing human erythropoietin using same | |
EP0350052A2 (en) | Transgenic animals transformed with autonomously replicating sequence-containing plasmid | |
US6018039A (en) | MC26 gene expression-regulatory region | |
RU2390562C2 (en) | Method of creating transgenic mammals which produce exogenous proteins in milk, and transgenic mammals created using said method | |
EP1135518A1 (en) | Transgenic animals as urinary bioreactors for the production of protein in the urine, recombinant dna construct for kidney-specific expression, and method of using same | |
JP2707466B2 (en) | Transgenic non-human animals | |
CA2200465A1 (en) | Improvement of an expression vector for production of recombinant proteins | |
KR100754114B1 (en) | - Cattle beta-casein gene targeting vector using homologous recombination | |
GB2331752A (en) | Vectors and YACs comprising an IRES | |
US20050043530A1 (en) | Seminal vesicle tissue-specific promoters and uses thereof | |
US20040266711A1 (en) | DNA sequences to target proteins to the mammary gland for efficient secretion | |
MXPA97002889A (en) | Improvement of a vector of expression for the production of proteins recombin | |
JP2000300115A (en) | Milk of non-human mammal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |